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Foreword
Recent advances in information and communication technology (ICT), biochemistry and
engineering are creating a new range of environmentally-friendly replacement products which
can be made from agricultural and other renewable feedstock. Referred to as bioproducts, these
products are biologically-based commercial or industrial products other than food, feed and
medicines made with biological or renewable agricultural (plant or animal), marine or forestry
materials.
In an effort to better define the size and structure of the bioproducts industry in Canada,
Agriculture and Agri-Food Canada (AAFC) commissioned Statistics to conduct the Bioproduct
Development Survey in 2004. This report analyses summary tables generated by Statistics
Canada representing the responses to the survey questions provided for the year 2003 and
provides a basis and benchmarks for future research into size, structure and activity of the
Canadian bioproduct industry. It helps us better understand the drivers behind developing
bioproducts, the challenges facing the industry and the gaps in knowledge that may require
future research to enable the Canadian bioproducts industry to grow.  
Overall, there were 232 bioproduct firms in Canada in 2003.  Firms were predominantly situated
in Quebec, Ontario, BC and Alberta with 82% of firms residing in these four provinces. While
each region exhibited varying degrees of strengths and weaknesses, Quebec and Alberta were
leaders on many dimensions (i.e. R&D, revenues, financing) while Atlantic Canada and
Manitoba lagged behind the rest in several areas. Bioproduct development in Atlantic Canada
appears to be behind the rest of the country with relatively low levels of research and develop-
ment and limited success in accessing funding. Quebec, with the most firms in Canada, seemed
to be highly successful in creating an environment where new firms could enter the sector and
access knowledge and partnerships with universities and private firms as well as both public
and private funding.  
Firms were also organized according to firm size. In 2003, there were 154 small (< 50 employees),
40 medium-sized (5-149 employees) and 38 (> 149 employees) bioproduct firms. Small firms
were in the process of developing/producing 574 bioproducts while medium and large firms
had 222 and 252 bioproducts, respectively. Although small firms had the largest number of
products, large firms averaged the largest number of products per firm (6.6), average total
revenue per firm ($244,654) and average R&D per firm ($2,906). Bioproducts Development Survey: Analysis of the Summary Results xii
Bioproducts development is taking place in many different industries including bio-fuels, bio-
chemicals, bio-energy, bio-plastics and bio-fibres. In 2003, most bioproducts were developed/
produced in the field of bio-chemicals. Bio-chemicals accounted for 432 (41%) bioproducts with
bio-fuels ranking second with 201 (19%) bioproducts. To develop these bioproducts, firms look
to numerous sources of biomass to convert into new products. Biomass sources include agricul-
tural, forestry, marine, animal manure and organic wastes. Agricultural biomass is the most pop-
ular type of feedstock preferred by firms with 93 firms reporting the use of agricultural biomass
in their operations. Forestry biomass ranked second with 77 firms using forestry products and
byproducts as their preferred biomass.
As an emerging sector, bioproduct firms tend to be young with 65% of firms being involved in
bioproduct development and production for less than 10 years. These firms have entered the sec-
tor in different ways (i.e. start-ups, spin-offs, corporations extending their core activities) and
usually maintain bioproduct development as only a portion of total firm activity. In 2003, nearly
all firms became involved with bioproducts as either the result of internal R&D (66% of firms) or
began as a spin-off from either universities or other firms (32%). Some firms devote all of their
resources to bioproducts while other firms see bioproduct development as a complementary
activity to already established operations. Overall, bioproduct activity accounted for less than
one-third of total employees and one-quarter of total firm revenues.
This report examines additional characteristics related to bioproduct firms such as intellectual
property (IP) rights, collaborative arrangements and provides in-depth coverage of regional/
provincial and size aspects. Because the analysis is based solely on tables provided by Statistics
Canada, it has not allowed this report to go beyond surface level analysis but provides a basis
and benchmarks for further research into the size and structure of the Canadian bioproduct
industry. Bioproducts Development Survey: Analysis of the Summary Results xiii
Executive summary
Bioproducts are non-food products developed from biomass originating from agricultural, food,
forestry, marine and industrial and municipal sources.  This report analyses the results of the
first Canadian survey of bioproducts firms commissioned by Agriculture and Agri-Food Canada
and conducted by Statistics Canada in 2004.  This analysis is performed using summary tables of
the responses to the survey questions provided by Statistics Canada.  The summary tables were
organized on two dimensions, by region/province and by firm size.  Some of the key results of
the analysis are presented by region and firm size in Summary Tables 1 and 2 respectively.  
For most of Canada’s 232 bioproducts firms, bioproducts are just one part of the business acti-
vities, accounting for less than one third of employees and slightly more than one quarter of total
firm revenue. Most firms (66 percent) entered the bioproducts business as a result of internal
research and development.  Only eighteen percent started as spin-offs, usually from universities
(64 percent of spin-offs) or other firms (32 percent).  The major benefits from bioproducts were
new product/market opportunities, but environmental benefits and benefits related to product
performance and production costs were also significant. Reducing energy was a low rated
benefit from bioproducts except for large firms and firms in Atlantic Canada and B.C.  
Capital was the most commonly cited factor limiting the expansion of bioproduct activities.
Although financing was a challenge, only 47 percent of Canadian bioproducts firms took advan-
tage of the Scientific Experimentation and Research Development Tax Credit program. Cost and
timeliness of regulatory approval was the second most cited barrier to expansion and it ranked
among the top three barriers in all firm sizes and all provinces except Manitoba and Alberta.  A
related issue, lack of product standards or certification, was relatively highly rated across
Canada and for both small and large firms.  Problems related to intellectual property, negative
public perception or acceptance and human resources were generally not seen as major inhi-
bitors to bioproducts expansion.  
The importance of knowledge to the bioproducts sector was revealed in firm strategies.  Acquir-
ing industry knowledge was rated as the top knowledge management strategy across all firm
sizes and five of the seven regions.    Firms used a combination of internal and external know-
ledge management strategies, accessing external knowledge from industry and research insti-
tutions while at the same time promoting employee development. Quebec firms were more
focused on intellectual property (IP) management and were the most successful at acquiring IP.Bioproducts Development Survey: Analysis of the Summary Results xiv
Summary Table 1 highlights some of the provincial differences.  While each region exhibited
strengths, Quebec and Alberta were leaders on many dimensions while Atlantic Canada and
Manitoba lagged behind the rest on several measures.  Bioproduct development in Atlantic
Canada appears to be behind the rest of the country with relatively low levels of research and
development and limited success in accessing funding. Quebec, with the most firms in Canada,
seemed to be highly successful in creating an environment where new firms could enter the
sector and access knowledge and partnerships with universities and private firms as well as both
public and private funding. Although Ontario had the highest overall revenue from bioproducts,
it lagged on several dimensions: attracting companies into bioproducts, developing new prod-
ucts, securing IP, raising money and using government programs, relationships with other firms
and expenditures on both general and bioproducts R&D.  With the lowest percentage of firms
entering the sector in the last five years and the highest percentage of public companies,
Manitoba gives the impression of an older sector more focused on production than on generating
new products and firms.  Although Manitoba led Canada in average bioproducts R&D expendi-
ture/firm, it was the least active region in terms of numbers of firms, total employment in the
sector and reported IP assignments.  Saskatchewan had many new entrants but with most firms
starved for cash and having to lever their relatively small expenditures on R&D by being the
most active collaborators with universities and other firms.  Alberta bioproducts firms appear to
be very well funded, active in product development and committed to bioproducts.  R&D expen-
ditures were the highest in Canada and bioproducts R&D was among the highest and they had
the highest average number of products under development (5.4/firm) with almost two thirds
on the market.  Bioproducts employees per firm, revenue per firm and bioproduct revenue per
firm were the highest in Canada, with most bioproduct revenue coming from exports. In terms
of characteristics like product development, employment and revenue, B.C. was in the middle of
the pack. Still, financing was a challenge, with much of 2003 funding coming from government
sources.  
For Canada’s 154 small bioproducts firms, bioproducts were a large proportion of their business,
with a significant percentage of their employees and R&D targeted at bioproducts.  They were
more heavily involved in the development of early stage products, more likely to have IP and
also more likely to export, with over 61 percent of bioproducts revenue from exports. Capital
was the major barrier to expansion but surprisingly small firms that sought capital were more
successful that their larger counterparts.  
Of the 40 medium sized bioproducts firms in Canada in 2003, 37 percent were public and 44 per-
cent were subsidiaries of multi-national corporations. Of their average of 98 employees, 69 were
devoted to bioproducts and 70 percent of those were either scientists or technicians. They spent
$1.5 million/year on R&D, but only 34 percent went into bioproducts. They had an average of 5.5
products/firm, with 74 percent of those on the market. They were the least likely to have bio-
products IP (15 percent) and the least likely to be involved in collaborations (15 percent). Unlike
small or large firms, medium sized firms secured the majority of their revenue from bioproducts.
In general, large firms were involved in bioproducts as a minor sideline or supplement to their
main businesses, often using by-products of their other businesses. Only 19 percent of employees
were involved in bioproducts and 18 percent of their revenue came from bioproducts.  They
were more active in using forestry products and in developing bio-fuels. They are more likely to
be public (60 percent) and foreign owned (40 percent) than smaller firms.  They appeared to have
significant difficulty raising money.  Research and development expenditures were lower as a
percentage of revenue than for smaller firms.  Large firms spent almost $3 million on total R&D
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Summary Table 2: Key Bioproduct Firm Indicators by Firm Size (2003)
Firm Size
Category Small Medium Large
Number of Firms 154 40 38
Firm Characteristics
% less than 5 years in bioproducts
% Public companies
# of employees/ # BP employees














% as a result of internal R&D 72.0% 47.1% 60.4%
Biomass Use:
Top Three Biomass Sources
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transportationBioproducts Development Survey: Analysis of the Summary Results xvii
Introduction
Canada, like many other countries, has been actively developing bioproducts and promoting the
companies behind them.  To better understand the Canadian bioproducts sector, Agriculture
and Agri-Food Canada (AAFC) commissioned Statistics Canada to undertake the first national
bioproducts survey in the world.   The survey was based partially on the Biotechnology Use and
Development Surveys administered by Statistics Canada every two years.  The Bioproducts
Development Survey was administered in 2004 with firms required to answer questions and
report results based on their 2003 data.
This report is the first examination of the results of the survey. The data for this report was
provided by AAFC from tables supplied by Statistics Canada.  Data was provided in the form of
tables summarizing responses to the survey questions by province and by firm size; small,
medium or large
1. The analysis which follows is based on those two methods of classifying the
data. Unless noted, all data in this report was derived from the results of the Bioproducts Devel-
opment Survey. The data captured in the survey and reported in this paper is 2003 firm data,
unless otherwise noted.  The limitations on the analysis are discussed in the following section.
The report is organized into key sections as follows. The first section discusses the limitations
imposed by the data used in the study. This is followed by an overview of the analysis and
summary of the key results of the study, which is designed to act as a stand-alone document.
The overview reports common themes found in the results and some of the most significant
differences between provinces and firm sizes.  Next, the main body of the report begins with an
examination of the structure of the Canadian bioproducts sector and the firms in the sector. The
second section examines the products being developed and the use of biomass by firms in the
sector. Succeeding sections examine bioproducts revenue and the factors that play a role in
revenue and expenditures, intellectual property, contracts and collaborations, human resources.
These are followed by an analysis of benefits from and barriers to bioproducts development and
commercialization. The next section considers an analysis of the business strategies used by
bioproducts firms. The final section includes concluding remarks examining the differences
between provinces, suggestions for improvements to the survey instrument and recommen-
dations for further analysis. 
1.  Statistics Canada noted that the data provided is preliminary and may be subject to revision in the future.Bioproducts Development Survey: Analysis of the Summary Results xix
Limitations
This report is intended to provide an initial analysis of the bioproducts sector using data tables
provided by Statistics Canada. All tables and figures in this report are derived from the
Bioproducts Development Survey and contain responses based on 2003 activity and the
summary tables provided by Statistics Canada. The authors had no access to the original survey
data. In cases where data was deemed by Statistics Canada to be unreliable, the data in question
was replaced with an F.  If data was deemed to possibly compromise the confidentiality of a firm
the data was withheld and replaced with an x.
The data analyzed in this report was organized and reported on two dimensions. The first is
regional, with data provided for the Atlantic provinces as a single region and for each of the
remaining six provinces individually. The second categorization is by firm size, measured by the
number of employees. Firms are classified as small (less than 50 employees), medium (50-149
employees) and large (more than 149 employees).  For this initial analysis, data was not provided
on any other dimension and so the analysis necessarily is performed on these two dimensions.
The presentation of the data also prohibited analyzing on the two dimensions simultaneously. It
is therefore not possible to analyze the number of firms of each size in an individual region. The
authors had no access to the underlying survey results and could not perform any additional
analysis beyond the two dimensions provided.  It is the intention of AAFC to perform a more in-
depth analysis in the future, but that is beyond the scope of the data provided. This analysis
reveals that the survey has provided a rich data set for a more in-depth analysis of the bio-
products sector.Bioproducts Development Survey: Analysis of the Summary Results xxi
Overview of the Bioproducts 
Development Survey Results
The survey studied bioproducts use and development in Canada.  For the purposes of the survey
bioproducts were defined as those products which were derived from biomass, specifically
biomass from agricultural crops, forestry, marine & aquaculture, food processing, animal
manure, industrial and municipal organic waste.  In 2003, the bioproducts sector in Canada
exhibited striking regional differences on some dimensions but similarities on others. Some of
the key characteristics of Canadian bioproduct firms are identified by region in Summary
Table 1, and by firm size in Summary Table 2.  
Common Themes in the Canadian Bioproducts Sector, 2003
Bioproducts are just one part of firm business activities and the proportion decreases with firm
size - The first observation is that, in general, bioproducts was just one part of the business activ-
ities of most of the 232 Canadian firms involved in bioproducts in 2003.  Canadian bioproducts
firms had less than one third of their employees involved in bioproducts and derived just over
one quarter of their revenue from bioproducts activities.  Almost half of firms secured their
inputs from by-products and most of the rest as primary products purchased as inputs. 
Bioproduct firms generally entered the business as a result of internal R&D - Almost two thirds
of firms (66 percent) entered the bioproducts business primarily as a result of internal research
and development.  Only 18 percent entered as spin-offs, primarily from universities (64 percent
of spin-offs) or other firms (32 percent). The benefits firms received from involvement in
bioproducts varied significantly. The most common dealt with new product/market opportu-
nities, however firms also secured environmental benefits and other benefits related to product
performance and production costs. Except for Atlantic Canada and B.C., reducing energy was a
low-rated benefit from bioproducts. However, the recent increase in energy costs will almost
certainly increase both the interest in the development of bio-energy products and focus of
companies toward bioproducts as a means of reducing energy costs. This benefit was relatively
important only for large firms. Thus, there are many reasons for firms to enter the bioproducts
business and there is no obvious single motivation which can be used to promote the
bioproducts business in general.Bioproducts Development Survey: Analysis of the Summary Results xxii
Barriers to expansion include capital, particularly for small firms, regulation and access to
personnel - The factors limiting the expansion of bioproduct activities are relatively consistent
across Canada, with capital as the most commonly cited barrier and difficulties related to regula-
tory approval second. A closer look at data by size reveals that the dominance of capital is
related to the number of small firms in the survey. Access to capital is the major barrier for small
firms, who make up 66 percent of the population, but is less important for large ones. However,
cost and timeliness of regulatory approval was among the top three barriers in all firm sizes and
all provinces except Manitoba and Alberta. Although not among the top barriers mentioned, the
related issue of lack of product standards or certification was relatively high-rated across Canada
and for both small and large firms.  It was not seen as a barrier by medium sized firms. 
One interesting finding regarding financing was that survey respondents generally did not make
good use of the Scientific Experimentation and Research Development Tax Credit program.
Across Canada the average participation was only 47 percent with smaller firms slightly more
likely to participate than larger firms.
Also of interest are the factors that were not cited as barriers – problems related to intellectual
property, negative public perception or acceptance and human resources were not seen as major
inhibitors, except for Alberta and B.C. firms who rated human resources as a moderate barrier.
The final area of similarity across firms and provinces related to firm strategies. Acquiring indus-
try knowledge was rated as the top knowledge management strategy across all firm sizes and six
of the seven regions.  Firms used a combination of internal and external knowledge management
strategies, accessing external knowledge from industry and research institutions while at the
same time promoting employee development.
Provincial Differences
A glance at Summary Table 1 shows that the differences between provinces are significant in
most sector indicators. Some areas of the country, particularly Quebec, Alberta and British
Columbia seem to be more successful in developing active, successful and growing bioproducts
sectors, while others have had more difficulty.  The differences highlighted here are discussed in
more detail in the main body of the report.
Atlantic Canada 
It appears likely that many of the bioproducts firms in Atlantic Canada are large forestry and
food companies which include bioproducts as one small part of their overall business.  Atlantic
firms lead Canada in the number of firms using both forestry and food processing by-products.
Interestingly, 60 percent of Atlantic firms produce bioproducts as primary products and almost
half of firms use them internally.  Both of these are significantly higher than the proportions for
firms in other provinces.   Few companies have entered the bioproducts business recently; only
21 percent in the last five years.
Since bioproducts is of lesser business importance Atlantic firms trail behind those of other
regions on almost every dimension of bioproduct business development.  Although the fifteen
firms in the region are the largest in terms of employment, they have the lowest average total
revenue of any region in Canada and the lowest percentage of bioproduct employees per firm.
Both general research and development and bioproduct research and development expenditures























































inadequate to maintain a significant bioproduct development presence. The fact that the firms
are in other businesses could explain the low percentage seeking financing, but those who
sought financing raised an average of only $407,000 per firm. Relatively few are public compa-
nies (19 percent), eliminating one potential capital source for most firms.  
Quebec 
Based on the data in this survey, Quebec is the leading province in new bioproduct develop-
ment.  The province has attracted many young firms to the bioproducts business, with 43 percent
of firms having entered in the last five years. The province was also home to 45 percent of
Canadian bioproduct spin-off companies, including the most new university and company
spinoffs.  Quebec firms had the second highest proportion of staff dedicated to bioproduct activ-
ities, the highest average number of products under development (5.1) and the highest percent-
age of firms with IP (43 percent). The latter reflects the very high emphasis that Quebec firms
place on intellectual property (IP) and the significant investments in bioproduct R&D. Quebec
was the only province where IP audits were viewed as one of the top knowledge management
strategies.   Quebec firms appear to be heavily involved in early stage development, and they
had the lowest percentage of products on the market. 
Numerous studies have shown the importance of intellectual property in securing funding in the
field of biotechnology. In the bioproducts industry the importance placed on IP may be one
explanation for the success of Quebec firms in securing financing and the fact that they raised the
second most funding per firm seeking financing. Firm revenues were lower on average in than
most provinces, as was the percentage of bioproduct exports, likely reflecting the younger age of
the companies.  
Accessing outside skills was important for Quebec firms, who had high levels of both collabora-
tions and contracts with private laboratories and universities. Of all bioproduct contracts in
Canada, 38 percent involved Quebec firms.
Ontario
Ontario firms were heavily involved in the use of agricultural crop biomass, with over half of
their inputs coming as by-products. Bioproducts were important to the province; firms in
Ontario saw $871 million in bioproducts revenue, the highest in Canada. However, with the
exception of products on the market, bioproduct employees and average revenue/firm, Ontario
firms lagged behind Quebec on many indicators of bioproduct activity. Ontario had difficulty
attracting new companies into the field and the companies in the business were not as active in
developing products (3.2/firm), securing IP (23 percent) or raising money, securing less than
25 percent of the amount raised by Quebec firms. Ontario firms spent considerably less on
general R&D and bioproducts R&D than other organizations and they had the lowest percentage
of firms contracting out activities and involved in collaborations in Canada. The proportion of
Ontario firms pursuing government funding was significantly below the national average.
Overall, Ontario firms were less active than firms in most provinces in both internal and collabo-
rative bioproduct development. The focus of Ontario firms was much more on producing
products for sale to outside organizations, with only 19 percent of firms producing for internal
use.  Bioproducts Development Survey: Analysis of the Summary Results xxiv
Manitoba 
Looking at Manitoba, one gets the impression of an older sector more focused on production
than on generating new products and firms. The province had the lowest percentage of firms
entering the sector in the last five years and the highest percentage of public companies. It was
the least active region in the bioproducts sector in terms of numbers of firms, total employment
in the sector and reported IP assignments. There were relatively few products in the research and
development stage but Manitoba firms appear to have the highest percentage of products/firm
in production or on the market in Canada. All the firms in Manitoba used agricultural biomass.
However, firms in the province are in the mid-range of both total and bioproduct revenue. It is
somewhat paradoxical that they are were the top end of R&D expenditure per firm and led
Canada in average bioproducts R&D expenditure per firm. Although Manitoba had relatively
few firms in the sector, those which were present appeared to be committed to bioproduct devel-
opment. 
Saskatchewan
New firms were entering the Saskatchewan bioproducts sector at a fair rate. Approximately
40 percent entered within the last five years and the province’s 3 spin-offs come from other
companies. Internal R&D spurred entrance into the sector for 85 percent of companies in the
region. Saskatchewan firms were actively using agricultural biomass, and made the greatest
effort of all regions to use animal manure.  Saskatchewan firms were slightly above average in
terms of products under development or production but they raised the least capital to fund that
development.  Spending on both general and bioproduct R&D was below all regions except
Atlantic Canada. The firms were the most active in collaborating with other organizations and
second most active in contracting. Although average revenue/firm was second in Canada,
bioproducts revenue was lowest and their spending on general R&D and bioproducts R&D was
the second lowest in Canada. They seemed to lever their R&D effort by collaborating heavily
with organizations of every type resulting in relatively high numbers of products under devel-
opment, albeit at the earlier stages than in most provinces. Continued sector development in
Saskatchewan will be constrained by the lack of capital.
Alberta 
Alberta bioproducts companies appear to have been well funded, active in product development
and committed to bioproducts. They had the highest average number of products under devel-
opment (5.4/firm) with almost two thirds on the market. Biomass inputs came from several
sources (notably agriculture, forestry and other sources) and most of the biomass was trans-
ported from distances of more than 50 km. Bioproducts employees per firm, revenue per firm
and bioproduct revenue per firm were the highest in Canada, with most bioproduct revenue
coming from exports. R&D expenditures were the highest in Canada and bioproducts R&D was
among the highest. Alberta firms could afford to spend more since, on average, firms seeking
funding raised over $7 million each in 2003, two and a half times the funding of the next closest
province (Quebec). Interestingly, low levels of IP did not seem to hamper attempts to raise
money. Most of the money raised came from private placements and IPO’s rather than from
government sources.  There is nothing in the data to indicate that Alberta will slow down and
























































B.C. is very active in the bioproducts field, with a mix of young and older companies. Of no
surprise is the fact that B.C. biomass came predominantly from the forestry products, with
64 percent either by-products or recycled product.  In many respects it was in the middle of the
pack in terms of characteristics like product development, employment and revenue. However,
in some areas the province appeared to be somewhat behind. Financing was a challenge, with
much of 2003 funding coming from government sources but the rest coming from a mixture of
private sources.  B.C. firms were second only to Quebec firms for total funding secured through
the SR&ED tax program. Both general and bioproduct R&D expenditures were below the
Canadian average but the number of products under development was typical. B.C. firms are
less active in collaborating with other organizations.
Firm Size Differences
The companies involved in bioproducts in Canada were also analyzed by firm size with firms
classified by the number of employees: Small (1-49 employees), Medium (50-149 employees and
Large (more than 149 employees). A summary of key results by firm size is presented in
Summary Table 2.
Small firms 
Canada’s 154 small bioproducts firms made up two thirds of the firms in Canada but with just
over 14 employees each they employed only 9 percent of the workers employed by the 232 firms
and just 22 percent of bioproducts employees. However, 77 percent of their bioproducts employ-
ees were scientists and technicians. They tended to be private (80 percent) and Canadian owned
(92 percent). They were more involved in the development of early stage products and in the
development of all products except bio-fuels.  Rather than using their own by-products they
usually had to secure raw materials from a distance and use foreign sources more than other
categories.  
Total revenue per firm was roughly $6 million per year, of which 45 percent came from
bioproducts. These small firms were active exporters with over 61 percent of bioproducts
revenue from exports. Although total R&D expenditure of $444,369 was lower for small firms,
bioproduct R&D expenditure was only half the level of large firms. These companies spent
72 percent of their R&D dollars on bioproducts. Small firms were much more likely to have
rights to IP than larger firms but only 35 percent of them had such rights.
Most entered the sector as result of internal R&D. The vast majority (86 percent) of the bio-
product spin-off companies were small firms. Small firms supplemented their internal develop-
ment capabilities by working with other firms and research institutions to take advantage of
industry knowledge. Collaborations were utilized by 43 percent of firms. As in other industries,
money is a major barrier to expansion; 60 percent of firms sought capital and $1.36 million was
raised on average. Of the 154 firms 30 secured funding from government grants, 24 from venture
capitalists and 24 from angel investors, while another 25 obtained funding from private place-
ments and initial public offerings. Bank loans, government loans and matching funding
programs were far less important.Bioproducts Development Survey: Analysis of the Summary Results xxvi
Medium Firms
There were only 40 medium sized bioproducts firms in Canada in 2003.  Of these firms
37 percent were public and 44 percent were subsidiaries of multi-national corporations. The
firms averaged 98 employees with 69 devoted to bioproducts (70 percent of which were either
scientists or technicians). With their larger resources they have more products under develop-
ment (5.5/firm) and had 72% of those products already on the market. They spent $1.5 million
on R&D but only 34 percent was allocated to bioproducts. They were the least likely to be
involved securing rights to bioproducts IP (15 percent) and the least likely to be involved in
collaborations (15 percent).
Medium sized firms were the most active users of agricultural crop biomass (54 percent) but
many used forestry biomass (30 percent). They were more likely to sell directly to consumers (78
percent) and to other firms (71 percent) with only 22 percent using the products internally.
These firms had significant business activity in bioproducts. On average their revenue was seven
times that of small firms at over $43 million per firm, and 63 percent came from bio-products.
Their main strategies focused on increasing revenue, particularly through entering foreign mar-
kets. They perceived significant benefits from bioproducts in terms of both improved value and
performance and in increased sales.  
Only 45 percent of medium-sized firms looked for money, and they raised less than small firms
from matching funds (15), collaborations (6) and grants (5) and banks (5).  They also received
nearly as many credits under the Scientific Research & Experimental Development tax program
as large firms, averaging $2.3 million per firm.  The firms used their funding primarily for R&D
and proof of concept studies.
Large Firms
In general large firms were involved in bioproducts as a minor sideline or supplement to their
main business and their responses to survey questions repeatedly reflected that fact. Being larger
they are more likely to be public (60 percent) and foreign owned (40 percent) than smaller firms.
Forestry companies figure prominently among large firms with 70 percent securing forestry
biomass compared to 30 percent and 25 percent for medium and small firms. They dominated
small and medium firms in the development in bio-fuels. Over half of large firms used by-
products in their processes and they sourced much of their biomass on site or nearby. Revenue
was significantly higher than in other classes ($245 M/firm). Only 18 percent of their revenue
came from bioproducts with 41 percent of that from exports. Although large firms had relatively
more revenue, 31 percent still sought financing; however, they appeared to have substantial dif-
ficulty raising money, securing far less than smaller firms. Few obtained more than half of their
target. The average of $485,000 secured/firm was less than half that of medium firms, and barely
over one third of the average amount typically raised by small firms which sought financing.
Money came primarily from matching funds (8), banks (3) and grants (3). Most sought funding
to increase production capabilities (91 percent) or to further production development through
R&D and proof of concept studies (76 percent).  
The firms averaged 476 employees per firm with 19 percent devoted to bioproducts. They have
significantly more production/management employees but only twice the scientific and tech-
nical employees per firm that small firms have. Research and development expenditures were
lower as a percentage of revenue than for smaller firms.  Large firms spent almost $3 million on
























































The different strategies and challenges of firms from different size and regions generally neces-
sitates distinct policies to promote bioproducts among Canadian companies. However, the
common themes point out some reasonable starting points at the national level.
One pressing issue identified was the time and cost associated with the bioproduct approval
process. This was a challenge to firms across regional and size categories.  It is worthwhile inves-
tigating why this issue was raised so regularly and what can be done to improve the situation.
One aspect of any review should deal with product standards and certification since this could
be one factor in the regulatory approval process.  
Addressing the lack of capital is a different matter since it involves small firms in a new technol-
ogy area.  While individual programs may be targeted at the bioproducts sector, programs
aimed at promoting new technologies in general may help to create an environment conducive
to the creation of new companies in a variety of technology sectors.  Capital supplies are imping-
ing on the ability of firms to attract highly qualified personnel. Although firms did not identify
human resources as a major barrier, when asked about difficulties in filling positions, the impact
of capital restrictions on small firms became apparent - lack of capital was cited as the main
reason for not filling positions across Canada.  
A related issue is the relatively low uptake and variability of government support programs.
Just under half of firms used the Scientific Research and Experimental Development tax credit
programs and roughly one third accessed both federal and provincial support programs.
Frequency was inversely related to firm size, with smaller firms taking greater advantage of the
programs across a broader range of activities. The differences by region were huge with Quebec
the leading user of programs and Alberta firms least likely to access support. One obvious
conclusion is that different approaches are required depending on whether the target is promo-
tion of bioproducts development in large firms or increasing the number and success of small
bioproducts firms focused on developing new bioproducts. Large firms incorporate bioproducts
into their existing businesses for environmental, cost and market reasons; therefore, such a move
must make sense on those terms. Support programs that promote such developments would
have an impact.  Small firms build a major portion of their business on bioproducts and commit
a significant percentage of their scientific development resources to those products. They tend to
require and use assistance in every area from technology development to loan guarantees and
training since a lack of both financial and personnel resources are significant factors limiting
their development.
From a provincial perspective, further analysis would allow for better understand of the differ-
ences and would be an essential input to the policy creation process. The obvious starting points
would be a regional analysis cross-tabulating firms by location, product line and size to better
understand the composition of the regional sector and the challenges facing the region.The Canadian Bioproducts Development Survey - 2003 - Analysis of the Summary Results xxix
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Chapter 1
Canadian Bioproducts Businesses
Two hundred and thirty-two firms across Canada participated in the production or development
of bioproducts during 2003.  Quebec, Ontario, and British Columbia are home to most of these
companies; 31 percent, 23 percent, and 16 percent respectively of all firms were located in these
provinces (Figure 1).  Revenue for these firms in 2003 totaled just under $ 12 billion.  However,
bioproducts revenue was just over $ 3 billion and 47 percent of the bioproducts revenue was
from exports of bioproducts. 
Figure 1:  Bioproducts firms by province, 2003
The bioproducts sector is dominated by small firms, at least in terms of numbers. Approximately
66 percent are small in size with less than 50 employees. Of the remaining firms 17.2 percent
were medium sized with 50 – 149 employees, and 16.4 percent were large firms with more than
149 employees. 

























Many of the firms surveyed have been in the business of bioproducts for a relatively short period
of time. Sixty-five percent have been involved in bioproduct-related activities for 10 years or less.
Quebec, Alberta and Saskatchewan appear to have created environments conducive to the
creation of new bioproducts firms. Forty-two percent of Quebec firms are five years old or less,
and about thirty-nine percent of firms in Alberta and Saskatchewan are in that category
(Table 1). In all other regions in Canada less than thirty-five percent of firms are five years old or
less. 
The proportion of firms under 10 years of age was markedly higher for small firms (75 percent)
and lower for large firms (36 percent). Nearly half of large firms reported involvement in the
sector for over 20 years. 
Entry into the Bioproducts Sector
Approximately 19 percent of Canadian bioproducts firms originated as spin-offs (Table 2). Not
surprisingly, most are small (86 percent), a few are medium (14 percent) in size and none were
large. The vast majority originated from either universities (64 percent) or other firms
(32 percent).  Quebec had the largest share of spin-off companies, with 20 of the 44 Canadian
bioproducts spin-offs. Eight of those companies have been spun out of another firm rather than
out of universities, representing 57 percent of all Canadian spin-offs from companies. The results
regarding company spin-offs display significant regional differences. Alberta and Ontario
spinoffs are almost exclusively from universities, while Saskatchewan and British Columbia’s
small number of spin-offs came solely from other firms. Government agencies did not figure
prominently in bioproduct company spin-offs.
Although spin-offs are an important means of creating new bioproducts firms, most companies
entered the bioproducts field as the result of internal company research and development, as
illustrated in Figure 2.  Other entry methods were far less frequent.
Table 1: Number of years of involvement in bioproducts, 2003
Region Number of firms 10 years or less 5 Years or less
#%%
Canada 232 65.1 34.5
Atlantic 15 60.0 20.0
Quebec 72 77.8 43.1
Ontario 53 58.5 30.2
Manitoba 9 33.3 33.3
Saskatchewan 18 61.1 34.5
Alberta 27 74.1 40.7
































Figure 2:  Initial entry to the bioproducts sector, 2003
Ownership
Ownership among Canadian bioproducts firms varies with location (Table 3) and company size
(Table 4). Bioproducts firms in Manitoba, Alberta and B.C. are much more likely to be public
companies than those in other provinces. Only Manitoba has a relatively high proportion of
foreign owned companies compared to the other regions.
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Large firms are far more likely to be public companies, and more likely to be foreign owned.
Although only 18 percent of firms are subsidiaries of multi-national corporations (MNC’s), this
increases to 44 percent for medium sized firms.  Canadian ownership is highest among small and
medium sized firms with non-U.S. firms owning the majority of non-Canadian bioproducts
companies.  However, among large companies U.S. ownership is quite high at 28 percent.


























Canada 232 29.3 18.1 83.6 9.1 6.5
Atlantic 15 18.9 - 93.3 - 0.0
Quebec 72 20.9 9.7 87.5 6.9 2.8
Ontario 53 25.6 24.5 83.0 7.5 9.4
Manitoba 9 65.1 33.3 66.7 33.3 0.0
Saskatchewan 18 - - 88.9 - 0.0
Alberta 27 43.9 29.6 70.4 11.1 18.5
British Columbia 38 45.0 21.1 84.2 7.9 7.9
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154 19.8 8.0 91.9 3.9 5.2
Medium
(50-149)
40 37.1 44.0 74.1 10.5 13.8
Large
(>149)
38 60.1 31.5 60.3 28.1 6.8Bioproducts Development Survey: Analysis of the Summary Results 5
Chapter 2
Bioproduct Development and 
Biomass Use
Bioproduct Development
Canadian firms are actively developing and producing a variety of bioproducts. In 2003, the
firms had a total of 1,048 products under development or in production, an average of 4.5
products/firm. Of these, 60 percent were already on the market, 18 percent were mid-deve-
lopent, and 22 percent were in early stages. The largest category of products was bio-chemicals,
which made up 41 percent of all bioproducts (Figure 3). 
Figure 3:  Bioproduct development by product type, 2003 











































































As one would expect, small companies were more focused on the early stages of research and
development than the larger firms (Figure 4). In any technology development process there are
typically more products in the early stages of development and much of the research and devel-
opment and proof of concept work is done in small firms.  As products are developed, many are
trimmed as they are found to be infeasible or to have no technological or commercial advantages
over existing products. Medium sized and large companies have the resources to produce and
market a limited number of commercial products so they dominate the last stage of develop-
ment. It is interesting to note that in the bioproducts sector more products are on the market than
in development.
Figure 4:  Product development by stage shown as a percentage of total products under development 
With one exception, product development patterns were fairly consistent across all product
types with small firms having the largest number of products under development. The exception
is in bio-fuels/bio-energy products where the largest number of products is under development
in large companies and 43 percent of large firms were engaged in the production of biofuels/
bioenergy.  This was more than double the number of large firms producing any other single
product type (Figure 5).  This result reflects the nature of the chemical and energy businesses,
which are dominated by large companies with significant resources.
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Figure 5:  Bioproduct development by product type and firm size, 2003 
Biomass Use
Firms were asked to indicate the type of biomass product used in 2003.  Table 5 provides a break-
down of responses to this question on a regional basis.  (Note that responses to this question are
not mutually exclusive, so the percents in any given column can sum to more than 100 percent.)
Agricultural crop and forestry biomass were the most common forms of biomass used in
Canada.  They were used by 93 and 77 firms, respectively, more than twice the number of firms
using any other single type of biomass. 
Agricultural crop biomass was favoured by firms in most provinces, including Manitoba,
Saskatchewan, Ontario, Alberta, and Quebec.  Firms in British Columbia and the Atlantic regions
made significantly more use of forestry biomass, while Quebec firms made fairly extensive use
of both forestry and marine biomass.  Firms in the Atlantic region made use of food processing
products and by-products, in addition to agricultural crop and forestry biomass. 


























Canada 40.3 33.2 14.2 15.2 8.7 10.6 6.6 15.5
Atlantic 40.7 59.0 21.1 40.7 - 29.5 - 0.0
Quebec 35.2 28.3 26.8 14.6 8.5 13.9 7.9 14.5
Ontario 51.5 24.4 2.0 8.7 4.4 5.7 5.7 24.2
Manitoba 100.0 - 0.0 0.0 0.0 0.0 0.0 0.0
Saskatchewan 44.7 27.7 0.0 - 28.8 0.0 0.0 21.2
Alberta 37.1 31.0 - 16.6 4.6 0.0 0.0 22.2
British Columbia 23.9 53.8 21.1 21.4 10.1 14.7 13.6 7.3
Number of bioproducts under development,






























Agricultural crop biomass was the dominant form used in both small and medium sized firms
(see Table 6). Large firms most often used forestry biomass in their production; however, very
little use was made of marine products, food processing products, animal manure, or municipal
organic waste.  
Table 6: Percent of firms by type of biomass used, by firm size, 2003
Table 7 shows the percentage of firms using biomass inputs of different origins.  This breakdown
is based on whether firms secure their main biomass input as primary products (e.g. soybean,
corn, hemp, etc.), by-products (e.g. straw, fat, etc.) or recycled products (e.g. cooking oil, indus-
trial sludge, etc.). Within Canada, most firms used either primary (108 firms) or by-product
(109 firms) based biomass inputs. Moreover, this pattern of biomass input type also appears to
hold across the different regions, albeit in different proportions. Regardless of firm size, most
used either primary or by-product based biomass inputs (see Table 8).
Table 7: Percent of firms by principal biomass input, by region, 2003
Most biomass inputs were sourced domestically.  At a national level, over 80 percent of firms
reported sourcing their biomass inputs domestically.  Except for Alberta, where one third of
firms sourced their inputs internationally, this pattern holds on a regional level. Firm size does
not appear to affect whether a firm sources their biomass domestically with medium sized firms


























Small 41.8 24.6 15.3 16.7 11.3 6.4 9.1 21.4
Medium 53.5 30.3 15.8 15.6 F 10.2 F F
Large 20.2 71.0 8.3 8.8 3.5 28.3 0.0 F
Region Primary product By-product Recycled product Foreign Source
-percent-
Canada 46.4 47.1 6.3 15.6
Atlantic 61.4 21.6 18.9 -
Quebec 46.2 47.1 6.2 18.2
Ontario 42.8 51.6 4.9 13.0
Manitoba 50.4 45.4 0.0 0.0
Saskatchewan 46.8 53.3 0.0 -
Alberta 57.5 43.0 0.0 33.2








































Only 18 percent of all Canadian firms had their biomass on site, and nearly 60 percent of firms
were farther than 50 km from their primary source (see Figure 6). With the exception of the
Atlantic region and Manitoba, more than half of the firms indicated that they traveled
50 kilometres or more to source their biomass inputs. This suggests that an active market with
substantial search and transport costs exists in the sourcing of biomass inputs. As will be seen
later, the cost of transporting biomass inputs is viewed by some firms as a barrier to bioproduct
development/production.  
Figure 6:  Percent of firms by distance from location of principal biomass input, by region, 2003
Off-site sourcing was important for small and medium sized firms which predominately sourced
biomass inputs from locations greater than 50 kilometres from the firm (Figure 7). As firm size
increases, the share of biomass input sourced on-site increases, a finding consistent with the
increasing level of by-product used with increasing firm size. This would suggest that smaller
firms were focused more on processing biomass not produced by the firm, while large firms
used biomass processing as a means to develop a revenue generating output based on some
other production process. Alternatively, larger firms may be adjacent to sources of their biomass
inputs, thus taking advantage of agglomeration economies.
Table 8: Percent of firms by principal biomass input, by firm size, 2003
Firm size Primary product By-product Recycled product Foreign Source
-percent-
Small 
(less than 50 employeees)
48.0 45.7 5.5 17.7
Medium
(50 - 149 employees)
44.0 48.0 8.0 10.6
Large
(more than 149 employees)
39.9 52.5 7.6 12.4
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Figure 7:  Percent of firms by distance from location of principal biomass input, by firm size, 2003
Table 9 summarizes firm’s responses regarding where their bioproducts were sold or used.
Within Canada as a whole, most firms (65 percent) indicated they sold their bioproducts directly
to consumers or distributors, followed by 47 percent who reported sale to another firm for use as
an intermediate input, and 33 percent who indicated their bioproduct is used internally. Note
that the responses to this question are not mutually exclusive, and the percentages in Table 6.1
could sum to more than 100 across a row.
Except for the Atlantic region and Manitoba, firms sell primarily to consumers or distributors,
followed by sales to other firms and lastly, for own use. In Atlantic Canada, 51 percent of the
firms reported sales to a consumer or distributor, or production of the bioproduct for own use,
while 31 percent reported sales of bioproduct as an intermediate input to another firm. In
Manitoba, sales of the bioproduct as an intermediate input to another firm was reported by
65 percent of firms, while 45 percent report sales to a consumer of distributed and 34 percent
reported production for own use.
Table 9: Percent of firms by end user of bioproducts, by region, 2003
Region
Sold directly to 
consumers or distributors
Sold to other firms to 




Canada 64.6 47.4 32.7
Atlantic 50.7 31.2 51.7
Quebec 62.6 51.3 37.2
Ontario 68.3 41.0 19.0
Manitoba 45.4 65.1 34.4
Saskatchewan 77.3 39.0 23.2
Alberta 69.2 53.2 47.2
British Columbia 63.8 51.0 29.4








Small (less than 50 employees) Medium (50 - 149 employees) Large (more than 149
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Also note that the size of firm appears to affect the end use of the bioproduct (see Table 10).  A
large number of small and medium sized firms reported selling direct to consumer or distribu-
tor, but fewer of these firms reported selling their bioproducts as an input to some other firm,
and even fewer still reported using their bioproduct for internal use.  In contrast, 67 percent of
large sized firms used their bioproducts for internal use; slightly over half of the large firms sold
directly to consumer or distributor and fewer still reported selling bioproducts as an input to
another firm.
Table 10: Percent of firms by end user of bioproducts, by firm size, 2003
Firm size
Sold directly to consumers 
or distributors
Sold to other firms to 
be used as inputs
Produced for internal 
use
-percent-
Small (less than 50 employeees)a 63.9 43.0 26.9
Medium (50 - 149 employees) 78.2 70.9 22.0
Large (more than 149 employees) 52.8 40.4 67.2Bioproducts Development Survey: Analysis of the Summary Results 13
Chapter 3
Bioproduct Revenue and 
Expenses
Bioproduct Revenue
Nearly $12 billion in revenue was generated by Canadian bioproducts firms in 2003 (Table 11).
However, just over one quarter (26 percent) of their revenue was derived from bioproduct
activities; Canadian bioproduct firms were not only active in the bioproducts area. We note that
with the exception of Saskatchewan and Alberta, firms in most provinces obtained more than
30 percent of their revenues from bioproduct activities. The largest total provincial revenue
figures came from Alberta, Ontario, and Quebec; Ontario had the highest provincial revenue
from bioproducts at $871 million. Firms from British Columbia generated the largest share of
their revenues through bioproduct activities compared with other regions, at 39 percent.
Saskatchewan companies received the lowest proportion of their revenues from bioproducts
(6.5 percent), over 75 percent of which was generated through bioproduct exports. Alberta firms
showed a similar dependence on exports, which accounted for 81 percent of their total bio-










Average revenue per firm displayed significant provincial differences (Table 12). Firms in
Alberta and Saskatchewan had significantly higher average revenue than firms in other
provinces but Alberta firms derived the highest average revenue from bioproducts, while
Saskatchewan firms derived the lowest. Revenues for Quebec firms seemed reflective of their
age. Average revenues were low relative to those of firms in other provinces and bioproduct
revenues made up a relatively large share, with a smaller percentage exported. British Columbia
firms displayed a similar pattern. 
Table 12: Average revenue/firm, by region 2003
Bioproduct revenues, as a percentage of total revenue also varied widely depending on firm size.
Medium sized firms derived the largest portion of total revenue and exports from bioproducts
(Table 13).  Large firms appeared to incorporate bioproducts into their companies as one line of
business, but not the major focus. Only 18 percent of total revenue and seven percent of export
revenue were derived from bioproducts.
Table 11: Revenue for bioproducts firms, by region, 2003
Region Total revenue Revenues from bioproducts





($000) ($000) % ($000) % %
Canada $11,961,964 $3,160,887 26.4 $1,502,307 12.6 47.5
Atlantic $404,497 F - - - -
Quebec $2,340,260 $785,066 33.5 $241,860 10.3 30.8
Ontario $2,791,291 $871,035 31.2 $422,581 15.1 48.5
Manitoba $390,462 $126,978 32.5 $74,945 19.2 59.0
Saskatchewan $1,543,943 $100,394 6.5 $78,710 5.1 78.4
Alberta $2,848,275 $624,399 21.9 $502,979 17.7 80.6














% of total 
revenue
($000)
% of total 
revenue
% of bioproduct 
revenue
Canada $51,560 $13,625 26.4% $6,475 12.6% 47.5%
Atlantic $26,966 F - - - -
Quebec $32,504 $10,904 33.5% $3,359 10.3% 30.8%
Ontario $52,666 $16,435 31.2% $7,973 15.1% 48.5%
Manitoba $43,385 $14,109 32.5% $8,327 19.2% 59.0%
Saskatchewan $85,775 $5,577 6.5% $4,373 5.1% 78.4%
Alberta $105,492 $23,126 21.9% $18,629 17.7% 80.6%
































Table 13: Bioproduct firm revenue, by firm size, 2003
Bioproduct Research and Development Expenditures
As shown in Table 14, Canadian firms spent an average of just over $1 million on R&D for the
year, 39 percent of which was devoted to their bioproduct programs. Firms in Alberta, Manitoba,
and Quebec spent more than the average on both total R&D and bioproduct R&D.  Quebec firms
typically spent nearly twice as much as Ontario firms on both total and bioproduct research and
development. Although their R&D spending was lower, Ontario firms did utilize 46 percent of
their R&D spending to fund bioproduct development, which was the highest of any region.
Quebec firms were a close second with 43 percent of their total R&D budgets geared towards
bioproduct uses. On average Atlantic firms invested only $288, 251 for all R&D activities on
average, and only 12 percent of this was used for bioproduct programs.
As a percentage of total R&D, small firms were the most intensely focused on bioproduct devel-
opment, with seventy-two percent of R&D expenditures aimed at bioproducts (Table 15). Large
firms focused roughly a fifth of their R&D budgets on bioproducts R&D, spending only
marginally more than medium sized firms and almost double what small firms spent.
Firm size Total revenue ($000) Revenues from bioproducts ($000)















 Small $927,961 $6,026 $418,796 $2,719 45% $258,656 $1,680 61.8%
 Medium $1,737,167 $43,429 $1,100,449 $27,511 63% $578,081 $14,452 52.5%
 Large $9,296,837 $244,654 $1,641,642 $43,201 18% $665,570 $17,515 40.5%

















Canada $1,032,509 $403,006 2.0 39.0 3.0
Atlantic $288,251 $33,019 1.1 11.5 -
Quebec $1,326,609 $571,543 4.1 43.1 5.2
Ontario $673,718 $309,468 1.3 45.9 1.9
Manitoba $1,589,441 $640,525 3.7 40.3 4.5
Saskatchewan $562,151 $205,875 0.7 36.6 3.7
Alberta $1,911,127 $526,447 1.8 27.5 2.3











Table 15: Average research and development expenditures, by firm size, 2003





Smalll $444,369 $321,395 72%
Medium 1,516,962 $512,147 34%
Large $2,906,076 $618,863 21%Bioproducts Development Survey: Analysis of the Summary Results 17
Chapter 4
Intellectual Property
Thirty percent of all Canadian firms either possessed or had applied for some form of IP rights
during 2003 (Figure 8). Most obtained their IP through either a patent assignment or a licensing
agreement, with the former being most common regardless of province or size (Tables 16 and
17).  Tables 16 and 17 indicate only the number of firms with each type of IP source, but not the
number of arrangements. For example, a firm could have numerous licensing agreements with
Canadian and foreign firms but there would only be a single entry under licensing agreements
and one entry each under Canadian and foreign sources. 
Firms in Quebec took a much more aggressive attitude toward acquiring and protecting IP.
Quebec bioproducts firms were the most likely to have acquired or pursued IP protection for
their technology (43 percent of firms); this is compared with 30 percent of B.C. firms and just
23 percent of Ontario firms. Consistent with this finding, two of the three most important
knowledge development strategies (discussed later) used by Quebec firms pertained to IP;
specifically, conducting IP audits to ensure protection of technology at all development stages,
and developing firm policies for knowledge and IP protection. Firms in all other provinces rated
the acquisition/use of knowledge from industry sources as the most important. In fact, conduct-
ing an IP audit, which was most important to Quebec firms, was the least important factor in
knowledge development to Canadian companies overall.  
With the exceptions of Ontario and Quebec, the percentage of firms which possessed/pursued
IP rights during the year was fairly stable across the country, ranging from 28 percent to










Figure 8:  Percentage of firms with IP rights by region, 2003 
Ontario firms were the most likely to have obtained foreign IP.  Nearly 58 percent of Ontario
firms with IP had acquired it from sources outside of Canada.  Quebec firms, in contrast, were
least likely to have obtained their IP from foreign firms or institutions.  Firms in Alberta, B.C.,
and the Atlantic regions acquired 67 percent, 63 percent and 50 percent of their IP from domestic
sources.  (Note: Manitoba and Saskatchewan data are insufficient to make conclusions.)
Table 16: Intellectual property arrangements, by region, 2003.
(The number of firms which acquired IP in 2003 and the source of the IP)
Type of IP Source of IP




assignment Other Canadian Foreign
-number-
Canada 232 38 50 24 52 35
Atlantic 15 4 F 0 3 3
Quebec 72 16 19 16 28 14
Ontario 53 7 10 3 5 7
Manitoba 9 0 3 F F 1
Saskatchewan 18 F F 0 0 F
Alberta 27 4 6 F 6 3
British Columbia 38 4 9 F 9 5
Percentage of firms applied for/acquired/licensed in 
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Alberta British





















y Figure 9:  Number of firms which acquired by source of the IP, by region, 2003 
Small firms were also most likely to have acquired/pursued IP protection, with 36 percent
having done so.  This is also consistent with other areas of the survey, which indicate that the
small firms may be more involved in the early development of new technologies. It may also
have been related to their search for capital as IP is often an important factor in obtaining finan-
cing. Medium and large sized firms had relatively lower rates, at 15 percent and 25 percent
respectively. The proportion of firms which obtained IP from domestic sources varied from 50
percent for medium sized firms to 59 percent for small firms and 73 percent for large firms. As
will be discussed later, restrictions on IP rights were not considered one of the major impedi-
ments to the development of bioproducts. Despite this, the inability to obtain IP protection for
technology was the most common reason for lenders limiting or refusing capital to firms (see
financing section for details).
Table 17: Intellectual property arrangements, by firm size, 2003.
(The number of firms which acquired IP in 2003 and the source of the IP)
Type of IP Source of IP




assignment Other Canadian Foreign
-number-
Small
(less than 50 employees)
154 31 37 16 40 27
Medium
(50-149 employees)
40 3 4 3 5 6
Large
(more than 149 employees)
38 3 8 5 8 3











Atlantic Quebec Ontario Manitoba Saskatchewan Alberta British
Columbia










Figure 10:  Percentage of firms with IP, by firm size, 2003
Percentage of firms applied for/acquired/licensed in IP rights, 










Small (less than 50 employees) Medium (50-149 employees) Large (more than 149
employees)Bioproducts Development Survey: Analysis of the Summary Results 21
Chapter 5
Contracts and Collaborations
Canadian firms relied heavily on outside organizations for research and development activities,
to reduce costs and risk exposure and to access new markets. They accessed skills and capabili-
ties in other organizations in one of two ways, through contracts and through collaborations.
Contracts are straight-forward exchanges of services for money. They are the simplest to negoti-
ate and execute but may not always provide the best long-term access to required capabilities.
Consequently, many firms have undertaken to create more extensive and permanent relation-
ships with other companies through collaborations.
Contracts
Contracts were a significant part of operations for many firms. Canadian companies had nearly
$117 million in total bioproduct-related contracting in 2003. On average, 36 percent of all
Canadian firms had contracted out some part of their bioproduct activity during the year
(Figure 11). Firms engaged in contracting activities had 1.9 contracts on average. The percentage
of firms contracting was fairly stable across firm sizes, but varied to some extent by province.
Manitoba had the highest proportion of firms contracting out, at 48 percent. The lowest propor-
tion was in Ontario (only 24 percent). Alberta firms were the most involved in contracting out
bioproducts activities. The $76 million of contracts provided by Alberta companies represented










Figure 11:  Percentage of firms contracting activities, by region, 2003 
Most bioproduct-related contracts were with private research labs and universities.  Contracts
with these institutions comprised 40 percent and 37 percent, respectively, of all contracts
(Figure 12). Around 7 percent of contracts were with each of the remaining categories of institu-
tions (government labs, foreign firms, other).
Figure 12:  Contracting arrangements by partner type, 2003
Although Alberta had the highest expenditure on contracts, Quebec firms were the most active,
particularly involving contracts with private or government labs. In general, private labs and
universities comprised most of the partners in all provinces. Government labs were a more
common partner for Quebec firms. (It is difficult to comment on the number of contracts with
foreign firms, since we are missing values for both Atlantic and Ontario.)
Percentage of firms contracting out bioproduct-related 
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Columbia
Contracting out of bio-product related activities in Canada,
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Analysis of contracts by partner by firm size reveals the extent to which small firms rely on con-
tracts. Small firms tended to have more contracts with private labs than with universities, and
large firms had more contracts with universities than with private research labs. Results on a
contracts-per-firm basis are consistent with the above observations. Small firms clearly had the
most contracts per firm with private labs, government labs, and foreign firms. Large firms, how-
ever, had by far the most contracts per firm with universities, with more than double the number
for small companies. 
Collaborations
Thirty-five percent of bioproducts firms in Canada were involved in collaborations with other
organizations in 2003 (Figure 13). Firms in Ontario were least likely to be involved while
Saskatchewan firms were the most likely, at 58 percent, followed by Quebec firms at 41 percent.
Fifty-one percent of firms reporting collaborations cited the access to external scientific expertise
as the primary reason for collaborations (Table 20). Collaborations for that purpose made up
63 percent of all Canadian collaborations.  This appeared relatively common across all sizes and
regions.  Cost reduction related to R&D activities was the second motivating factor. 
Table 18: Total number of contracts, by partner type and region, 2003 





Canada 114 108 21 23 23
Atlantic 0 F 0 F 4
Quebec 50 39 12 7 9
Ontario 10 17 3 F 0
Manitoba 15 5 0 7 0
Saskatchewan 9 4 3 0 8
Alberta 14 16 0 0 3
British Columbia 16 25 3 3 0
Table 19: Percentage of contracting firms, by firm size, 2003





lab. Foreign firm Other
-percent-
Smalll 22.1 25.6 5.6 4.7 6.4
Medium 23.3 18.5 7.8 11.2 7.3










Figure 13:  Percentage of firms involved in collaborations, by region, 2003 
Figure 14:  Percentage of firms in collaborations, by firm size, 2003
Small firms again displayed their need to extend their capabilities and were more likely than
larger firms to be involved in collaborative arrangements (Figure 14). Their motivations were
primarily to access external skills not available inside the organization (Table 21). Small firms
were more likely to work with private sector organizations; labs, bio-products and non-bio-
products firms, than larger firms. Large firms, on the other hand, collaborated much more
closely with academic institutions, for both access to expertise and reducing the cost of R&D.
Percentage of firms involved in bio-product-related 









Canada Atlantic Quebec Ontario Manitoba Saskatchewan Alberta British
Columbia
Percentage of firms involved in bioproduct-related 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Foreign collaborations were relatively rare. Only 22 percent of bioproducts firms in Canada had
entered into foreign collaborations. Due to confidentiality reasons the only available data is for
Quebec, Ontario, Saskatchewan and B.C. who have 18, 9, 7, and 7 collaborations with foreign
partners, respectively.  Saskatchewan had the most firms involved, at 38 percent, and Ontario the
fewest (of the numbers given) at 16 percent. Data is reported for small and large firms only.
Only 23 percent of small firms had foreign collaborations, compared to 25 percent of large firms. 
Firms were also asked about the motivation for entering into collaborations with foreign firms,
rating each motivation on a five point scale. The overwhelming reason for entering into foreign
collaborations was access to foreign markets. This was consistent across all provinces and small
and large size categories (Tables 22 and 23). 















Small (less than 50 employees 93
Knowledge not available internally; 
access outside scientific expertise 51 29 73 44 14 11 171
Cost reduction related to R&D 
activities 25 32 5 5 8 0 49
Reduce risk exposure 9 3 F F 3 F 24
Other 8 6 19 0 0 0 24
Medium (50-149 employees) 6
Knowledge not available
internally; access outside scientific 
expertise
3FF 3F 0 7
Cost reduction related to R&D 
activities F00 F0 0 F
Reduce risk exposure F 0 F 0 0 0 F
O t h e r 360 00 0 6
Large (more than 149 employees) 25
Knowledge not available internally; 
access outside scientific expertise 11 0 9 24 14 10 57
Cost reduction related to R&D 
activities 800 1 4F 62 2
Reduce risk exposure 6 0 3 0 0 3 6















low Medium Moderately high High Weighted score
-number-
Canada
Knowledge not available internally; 
access outside scientific expertise 28.1 20.9 2.9 12.0 36.0 3.07
Cost reduction related to R&D activities 32.3 20.7 28.8 2.9 15.2 2.48
Reduce risk exposure 29.7 37.4 11.8 14.7 6.4 2.31
Access foreign market 0.0 9.1 11.9 16.1 62.8 4.32
Atlantic - Not reported
Quebec
Knowledge not available internally; 
access outside scientific expertise 23.9 34.2 0.0 9.0 32.9 2.93
Cost reduction related to R&D activities 23.9 35.2 23.4 8.6 9.0 2.44
Reduce risk exposure 21.2 35.6 8.6 24.9 9.8 2.67
Access foreign market 0.0 0.0 18.1 25.7 56.3 4.39
Ontario
Knowledge not available internally; 
access outside scientific expertise 17.6 35.0 0.0 18.4 29.0 3.06
Cost reduction related to R&D activities 32.1 0.0 49.5 0.0 18.4 2.73
Reduce risk exposure 32.1 67.9 0.0 0.0 0.0 1.68
Access foreign market 0.0 35.0 0.0 14.5 50.5 3.81
Manitoba - not reported
Saskatchewan
Knowledge not available internally; 
access outside scientific expertise 78.3 0.0 0.0 0.0 21.7 1.87
Cost reduction related to R&D activities 54.3 21.7 24.0 0.0 0.0 1.70
Reduce risk exposure 54.3 21.7 0.0 0.0 24.0 2.18
Access foreign market 0.0 0.0 21.7 0.0 78.3 4.57
Alberta
Knowledge not available internally; 
access outside scientific expertise 22.6 0.0 0.0 27.4 50.0 3.82
Cost reduction related to R&D activities 45.3 27.4 0.0 0.0 27.4 2.37
Reduce risk exposure 22.6 50.0 27.4 0.0 0.0 2.05
Access foreign market 0.0 0.0 27.4 22.6 50.0 4.23
British Columbia
Knowledge not available internally; 
access outside scientific expertise 32.7 23.7 0.0 21.3 22.3 2.77
Cost reduction related to R&D activities 32.7 0.0 46.0 0.0 21.3 2.77
Reduce risk exposure 32.7 23.7 21.3 22.3 0.0 2.33




































high High Weighted score
-percent-
Small (less than 50 employees)
Knowledge not available internally; 
access outside scientific expertise 40.4 25.3 4.2 8.4 21.7 2.46
Cost reduction related to R&D activities 46.4 16.9 24.0 4.2 8.4 2.11
Reduce risk exposure 38.1 27.3 16.9 8.4 9.2 2.23
Access foreign market 0.0 8.4 4.2 23.1 64.2 4.43
Medium (50 - 149 employees)
Knowledge not available internally; 
access outside scientific expertise 0.0 0.0 0.0 0.0 100.0 5.00
Cost reduction related to R&D activities 0.0 77.1 22.9 0.0 0.0 2.23
Reduce risk exposure 0.0 77.1 0.0 22.9 0.0 2.46
Access foreign market 0.0 0.0 77.1 0.0 22.9 3.46
Large (more than 149 employees)
Knowledge not available internally; 
access outside scientific expertise 0.0 17.5 0.0 33.0 49.6 4.15
Cost reduction related to R&D activities 0.0 0.0 50.4 0.0 49.6 3.99
Reduce risk exposure 16.6 50.4 0.0 33.0 0.0 2.49
Access foreign market 0.0 17.5 0.0 0.0 82.5 4.48Bioproducts Development Survey: Analysis of the Summary Results 31
Chapter 6
Financing
Of the 232 respondents from across Canada, 54 percent attempted to raise capital in 2003 to assist
in the development or production of bioproducts. Most firms attempting to secure capital fund-
ing were at least partially successful. The proportion of firms successful in securing at least
partial funding ranged from 75 percent to 92 percent depending on size (Figure 25). A total of
nearly $300 million was raised by the 96 successful companies.  
Not only were Quebec, Ontario and British Columbia home to the highest number of firms, but
companies in these provinces were also most likely to attempt to raise capital (Table 24).
However, funding success varied widely from province to province. Firms in Manitoba,
Saskatchewan, and Alberta had very high success rates in raising at least partial funding, but the
number of firms is relatively low and the amount raised varied dramatically. Quebec, on the
other hand, had a high number of firms and a success rate of 86 percent. Quebec firms secured
over half of the capital raised in Canada -- over $126 million in total for 2003, and $3.3 million/
firm which sought capital. Interestingly, firms in Ontario were least successful in obtaining fund-
ing with just over 57 percent of firms able to raise capital, and raising only $700,000/firm seeking
capital. Atlantic firms also found it difficult to obtain funding, with only two-thirds successful in
their attempts. Alberta firms raised nearly $93 million with an average of $7.5 million per firm










Small firms were more likely to attempt to secure financing than larger firms; 60 percent of small
firms across Canada tried to raise capital.  While they had a lower success rate than either
medium or large firms they raised the most on average.  The partial funding success rate was
highest for the large firms, however not as many pursued funding, and the average amount
raised was lower.  Interestingly, funding for large firms was, on average, much lower than for
small or medium sized firms and they achieved far less of their target funding (Table 25 and
Figure 15). 
Medium and large firms also were less likely to reach their funding target than small firms, likely
because they had higher goals.  Despite the fact that large firms were most likely to succeed in
raising funds, few were able to raise more than half their target amounts.  Of the small firms that
succeeded in raising funds, 77 percent raised at least half their target.





















Canada 232 124 53.6% 96 77.4% 297,476 1,280 2,378
Atlantic 15 6 39.2% 4 66.7% F x x
Quebec 72 44 61.4% 38 86.4% 147,438 2,055 3,339
Ontario 53 28 53.2% 16 57.1% 19,975 375 702
Manitoba 9 3 34.8% 3 100.0% F x x
Saskatchewan 18 9 49.9% 8 88.9% 2,011 111 211
Alberta 27 13 47.9% 11 84.6% 92,753 3,449 7,507
British Columbia 38 21 55.0% 15 71.4% 25,790 666 1,192
Table 25: Financing success, by firm size, 2003





# % # % ($000) ($000)
Small 93 60.4 70 75.3 $234,228 $2,468
Medium 18 45.0 15 83.3 $45,725 $2,539










Figure 15:  Firm financing success, by firm size, 2003 
The number one reason cited by firms for pursuing financing was to fund R&D (Table 26). Firms
across Canada were fairly consistent in their purposes for obtaining funding. As might be
expected, repaying investors and funding regulatory expenses were only considerations for
small firms (likely due to firm structure and relative “newness” to the sector). Similarly, medium
and large firms required more funding for production and manufacturing since they had more
products on the market.  Just over half of firms, regardless of size, cited the need for operating
capital as a purpose for raising funds.
The most common reason for limitations of capital requests was the lack of availability of capital
(Table 27). The other major reasons cited pertained to the development stage of the product/
technology (too early) or a lack of proven market demand. 
Table 26: Purpose of securing financing, by firm size, 2003
Number of firms
Purpose Small Medium Large
# % # % ($000) %
R&D purposes/
expand R&D capacity 77 82.3 17 92.1 9 76.6
Proof of concept/pilot project 52 55.4 15 83.9 9 76.6
Regulatory expenses 19 20.1 0 0.0 0 0.0
Production/manufacturing
capability 43 45.8 12 66.1 11 90.6
Operating capital 53 57.2 9 52.1 6 51.8
Repay current investors 18 19.5 0 0.0 - -
Other 10 10.5 - - 0 0.0
Total firms attempting to raise 
capital 93 100.0 18 100.0 12 100.0
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1-24% of Capital Target Raised 25-49% of Capital Target Raised










The funding received by these firms came from numerous sources. Government programs
comprised 45 percent of all sources of funding for Canadian firms. Other common sources
included private placements and angel investors/family (each 13 percent). Less frequently used
were financial institutions, public offerings, venture capital, and alliances/collaborations.
Quebec companies captured most of the funding, especially from venture capitalists, govern-
ment loan programs, public offerings, and alliances. Loan programs were often administered
provincially.  In addition, Alberta firms had a disproportionately high number of the private
placements, which might account for their very high levels of funding per firm relative to
companies in other provinces.





















Canada 19 7 15 8 47 0 27
Atlantic F 0 0 0 0 0 F
Quebec 4 3 3 4 19 0 4
Ontario x 0 7 x 10 0 11
Manitoba 0 0 0 x F 0 0
Saskatchewan 5 x 3 0 0 x 4
Alberta 3 0 x F 4 0 3
British Columbia 4 3 x F 11 0 3





















Small 19 7 13 8 26 0 24
Medium 0 0 F F 13 0 F










Figure 16:  Number of firms using different financing methods by region, 2003
Table 29: Sources of financing, by region, 2003
Sources Canada Atlantic Quebec Ontario
British 
Columbia Manitoba Saskatchewan Alberta
# of firms % % % % % % %
Canadian VC 10 0.0 100 0.0 0.0 0.0 0.0 0.0
Banks, etc. 15 F 22.2 29.5 20.7 x 0.0 16.9
Angel/family 19 x 36.1 26.5 x 0.0 21.0 x
Govt. loans 5 0.0 100 0.0 0.0 0.0 0.0 0.0
Govt. matching 
funds 23 x 24.9 19.7 31.4 F 17.1 0.0
Govt. grants 35 8.9 42.5 19.4 12.3 0.0 17.0 0.0
Govt. other 6 0.0 54.1 x 0.0 0.0 0.0 F
IPO/SPO 6 0.0 77.2 0.0 0.0 x 0.0 F
Private placement 20 0.0 36.6 13.4 27.5 F 0.0 51.5
Alliances, etc. 9 0.0 51.6 F F 0.0 0.0 F
Other 3 0.0 F 0.0 0.0 0.0 0.0 F





















































Table 30: Sources of financing, by firm size, 2003
Number of firms
Average % of total for each firm
raised from this source
Region Small Medium Large Small Medium Large
Canadian VC 10 0 0 4% 0% 0%
Banks, etc. 75 3 4 % 7 % 6 %
Angel/family 18 F x 7% F x
Govt. loans 50 0 1 % 0 % 0 %
Govt. matching funds 7 9 8 2% 16% 17%
Govt. grants 27 5 3 11% 2% 2%
Govt. other 33 0 1 % 4 % 0 %
IPO/SPO 60 0 2 % 0 % 0 %
Private placement 19 x F 10% x F
Alliances, etc. F6 F F 5 % F
Other xx 0 x x 0 %Bioproducts Development Survey: Analysis of the Summary Results 37
Chapter 7
Use of Government Support 
Programs
Use of funding under the Scientific Research and Experimental Development (SR&ED) tax
program varied widely among the provinces and firm sizes. Firms in Manitoba and Quebec were
much more likely to use the program but Manitoba and B.C. firms were far ahead in terms of the
amount requested by participating firms. Alberta was third, with all other regions trailing.
Small firms were more likely to use of the SR&ED tax credit program but they applied for and
received less than larger firms. Large size firms have been the most successful in securing tax
credits over the last five years. 
















# % $’000 $’000 $’000
Canada 90 47.4 87,198 792 1,299
Atlantic 4 26.7 F F 3,761
Quebec 38 65.3 28,813 613 1,173
Ontario 15 37.7 5,500 275 840
Manitoba 6 55.6 15,873 3,175 1,071
Saskatchewan 5 38.9 x x 315
Alberta 7 25.9 11,481 1,640 3,891










Participation in other government programs was also only moderate with approximately one
third of firms applying to federal programs and one third applying to provincial programs
(Table 33). With the exception of Quebec, applications to federal programs were above those of
provincial programs. In Quebec, participation in provincial programs was 70 percent, more than
double the national average.
Small firms made more use of support programs than larger firms but both small and large firms
used both federal and provincial programs with approximately the same frequency (Table 34).
Medium firms presented an interesting anomaly, making relatively little use of either category of
support programs but using provincial programs more frequently than federal programs. The
major support programs accessed were those providing support for technology development
but small firms also made extensive use of loan guarantees, information and training programs.
Medium and large firms accessed technology development and training primarily. Both small
and medium sized firms used provincial training programs more than federal programs. More
details on program use are found in Appendix 2. 














# % $’000 $’000 $’000
Small 77 50.0 21,792 283 795
Medium 19 47.5 26,079 1,373 2,321
Large 15 39.5 39,328 2,622 2,505
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Chapter 8
Human Resources
It is estimated that 24,195 people were employed by firms engaged in the development and/or
production of bioproducts in Canada in 2003 (Table 35).  Of these, the greatest proportion was in
Quebec, followed by Ontario, the Atlantic Provinces and British Columbia. Around 75 percent
were employed in large firms, with only nine percent employed in small firms, indicating that,
even though two thirds of the firms are small, large companies dominate the sector, at least in
terms of number of employees.
Within companies involved in the development and/or production of bioproducts, an estimated
7,864 of employees had responsibilities related to bioproducts. Around 32 percent of employees
in these companies were involved in activities related to bioproducts including scientific
research and development (1,022), technicians (1,007) and management, marketing, finance and
production (5,606), with the remainder (229) engaged in a variety of other related tasks.  Over
58 percent of employees with responsibilities related to the development and/or production of
bioproducts in Canada were employed by companies in Quebec or Ontario.
Table 35: Average employees per firm with bioproduct responsibilities, by region, 2003 
Region















Canada 24,195 104 7,864 34 33
Atlantic 4,007 267 228 15 6
Quebec 5,959 83 2,499 35 42
Ontario 4,075 77 2,065 39 51
Manitoba 928 103 285 32 31
Saskatchewan 2,824 157 216 12 8
Alberta 2,602 96 1,076 80 41










Table 36 provides a breakdown of employees in the bioproducts sector according to responsibil-
ity across provinces.  Over 38 percent of scientific research and development personnel were
employed in Quebec, with a further 22 percent in Ontario and 15 percent in British Columbia.
The Atlantic Provinces account for almost 8 percent of scientific research and development
personnel but only 3 percent of total employment in the sector. 
Around 43 percent of employees with responsibilities related to the development and/or
production of bioproducts were employed in large companies, with 35 percent employed in
medium companies and 22 percent in small companies (Table 37). The relative importance of
employees by responsibility differed markedly by company size.  In particular, small companies
accounted for 43 percent of all employees engaged in scientific research and development across
the bioproducts sector, but only 15 percent of those involved in management, marketing, finance
and/or production. By contrast, large companies accounted for 51 percent of management,
marketing, finance and/or production personnel but only 29 percent of employees engaged in
scientific research and development.
On an individual firm basis small firms committed half of their personnel to development and
far fewer employees were focused on production and management (Table 38). 








Canada 1,022 1,007 5,606 229 7,864
Atlantic 79 24 123 - 228
Quebec 390 358 1,720 30 2,499
Ontario 226 78 1,609 - 2,065
Manitoba 27 150 93 - 285
Saskatchewan 44 46 126 0 216
Alberta 99 198 778 0 1,076
British Columbia 156 153 1,155 - 1,496









Small 439 395 836 47 1,716
Medium 293 368 1,908 183 2,751















s Respondents to the survey were asked to indicate the importance of a variety of factors related to
efforts to fill bioproducts-related employment vacancies on a five-point scale from "low" to
"high". The factors considered of "high" or "moderately high" importance by the greatest propor-
tion of respondents were lack of expertise (42.5 percent) and capital/resources insufficient to
attract candidates (44.2 percent) (Figure 17), suggesting that the predominant difficulties faced in
attracting personnel related both to a shortage of appropriate candidates for positions as well as
their own firm's resource constraints. The unwillingness of candidates to relocate and competi-
tion for qualified candidates were considered of "low" or "moderately low" importance by more
than 52 percent of respondents.
Figure 17:  Degree of importance of factors related to efforts to fill bio-products-related employment vacancies, 
2003
There were some notable differences in the relative importance of factors in efforts to fill
bioproducts-related vacancies across provinces.  T a b l e  3 9  p r o v i d e s  a  w e i g h t e d  s c o r e  o f  t h e
relative importance of each factor in attempting to fill bioproducts vacancies by province. Com-
plete details may be found in Appendix 3. Lack of experience was a less significant problem in
the Atlantic Provinces, Saskatchewan and Manitoba, while lack of qualified candidates was
considered of greater importance in the Atlantic Provinces, Quebec and Alberta, but less impor-
tant in Saskatchewan, Manitoba and (to a lesser extent) Ontario and British Columbia.  Greater
importance was attached to competition for qualified candidates in efforts to fill bioproduct-
related vacancies in the Atlantic Provinces, Alberta and Quebec, but lower importance in
Manitoba, Saskatchewan and Ontario.









Small 2.85 2.56 5.43 0.31 11.14
Medium 7.33 9.2 47.7 4.58 68.78
Large 7.63 6.42 75.32 0 89.4






























There were also marked differences in the relative importance of factors in efforts to fill bioprod-
ucts-related vacancies by company size (Table 40). Small companies employees reported that
capital/resources were insufficient to attract candidates. Medium size firms found that lack of
qualified candidates, lack of experience and competition for qualified candidates were their
main problems. Larger companies indicated the unwillingness of candidates to relocate (perhaps
indicating that they recruited over a wider geographical area) and lack of experience as the most
important challenges in filling bioproduct-related vacancies.
Table 39: Importance of factors in efforts to fill bioproducts-related vacancies, by firm size, 2003












insufficient to attract 
candidates





Canada 2.72 2.48 2.98 3.18 2.73 2.50
Atlantic 2.73 2.44 3.02 3.23 2.68 2.60
Quebec 2.80 2.48 3.16 3.34 2.85 2.55
Ontario 2.56 2.32 2.86 3.28 2.62 2.37
Manitoba 2.34 2.99 3.01 2.35 2.69 2.32
Saskatchewan 2.79 1.70 2.63 3.00 2.07 2.31
Alberta 2.79 2.94 3.20 3.12 3.14 2.74
British Columbia 2.78 2.62 2.81 3.00 2.72 2.46
Table 40: Importance of factors in efforts to fill bioproducts-related vacancies, by firm size, 2003











insufficient to attract 
candidates





Small 2.76 2.33 3.06 3.42 2.69 2.44
Medium 2.53 2.47 2.65 2.58 2.69 2.76
Large 2.76 3.12 3.03 2.80 2.98 2.44Bioproducts Development Survey: Analysis of the Summary Results 45
Chapter 9
Benefits and Barriers
Benefits From Bioproduct Development and Production
Respondents were asked to rate the importance of various benefits obtained by their firms as a
result of bioproduct development or production. The importance of each benefit was rated using
a five point likert scale, where a low importance rating was scored as one and a high importance
score was rated as a five.  A weighted average of the scaled responses is calculated, with the
proportion of respondents selecting the various rating serving as weight. This weighted average
provides the importance score used to rank the various benefits.
For all firms in Canada, increased sales/market share were ranked as the most import (see
Table 41), followed by development of new market niches/new products, reduced damages to
the environment, improved product value/performance, increased product range, reduced
production cost and finally reduced energy consumption. For convenience, Table 41 has been










Note: The three highest ranked benefits are identified by bold and shaded text.
Across regions, either increased sales/market share, development of new market niches/new
products or reduced damages to the environment was the top ranked benefit (based on the
importance score). Moreover, these benefits are generally in the top three ranked benefits within
each region.  Exceptions do exist to this general conclusion.  For instance, in all but Atlantic
Canada, and Saskatchewan, improved product value/performance ranked higher than either
increased sales/market share, reduced demand to the environment or development of new
market niches/new products.  
Reduced production cost and reduced energy consumption were not viewed as important as
market growth/expansion and lessening the extent of environmental harm. On a regional basis,
however, firms in the Atlantic region, Manitoba, and B.C. ranked reduced production cost and
reduced energy consumption higher than other benefits. Regardless, a general conclusion one
might draw is that Canadian bioproduct firms view market growth as the main benefit of devel-
oping or producing bioproducts.
Responses based firm size (Table 42) indicate that small firms view the most important bio-
product benefits as developing sales, new markets and improving the value or performance of
their products. This was very similar for medium size firms except that reduced environmental
impact replaced new market development. Improved product value or performance had the
highest importance score for medium firms. The importance of environmental impact appears to
increase with firm size since large firms ranked reduced damage to the environment as the most
important.
The benefit rankings are not entirely unexpected.  One might expect smaller firms to be seeking
market expansion opportunities as a means to facilitate growth and sustainability. Medium size
firms, who might already have well developed product lines and markets, might well focus on
generating additional value (or performance) with existing products.  
Larger firms may view reduced environmental damage as very important as this lessens the
negative publicity they receive and mitigates any liability they may face arising from environ-
mental damage. Larger firms are often more visible and therefore subject to greater scrutiny, as
such it is even more important for them to act in an environmentally responsible manner.  Note
too, that reduced production cost and energy consumption had higher importance scores for




























Canada 3.93 3.86 3.82 3.68 3.51 3.27 2.76
Atlantic 3.75 3.80 4.02 3.31 3.31 3.73 3.62
Quebec 4.04 4.21 3.60 3.82 3.71 3.04 2.19
Ontario 3.96 3.56 3.95 3.58 3.55 3.23 2.83
Manitoba 3.92 3.27 3.22 3.53 2.36 3.06 2.96
Saskatchewan 4.42 4.86 4.53 4.38 3.93 3.68 3.14
Alberta 3.94 4.13 3.52 3.83 3.70 2.94 2.63






















larger firms than for small and medium firms. This suggests larger firms are more focused on
cost control than market growth.  Such differences in business strategy, based on firm size, are
not unexpected.
Note: The highest ranked benefit for each firm size is identified by bold and shaded text.
Barriers to Bioproduct Development and Production
Respondents were asked to rate the importance of various barriers their firm experienced in the
development or production of bioproducts. As with the benefits question, the rating of each
benefit was scaled using a five point likert scale and the responses were used to develop an
importance score for each barrier, on both a regional and firm size basis. Table 43 shows the
importance scores for the different barriers on a regional basis. Barriers have been sorted from
most to least important on a national basis. For bioproduct firms in Canada, lack of financial
capital, high cost and timeliness of regulatory approval and higher price of raw materials or
feedstock were the top three barriers, based on the importance scores. Except for Manitoba,
either lack of financial capital or high cost and timeliness of regulatory approval had the highest
importance scores across the regions. As well, these three barriers are generally the highest rated
barriers on a regional basis. One exception to this was the role of unreliable supply of raw
material or feedstock, which had the third highest importance scores in Quebec, Manitoba and
B.C. 
In Manitoba, the most important barrier was higher transport cost of main feedstock or raw
material. The latter ranking reflects the fact that Manitoba's central location makes it difficult to
get needed inputs. Given that bioproduct firms in Manitoba use agricultural crop biomass, and
that Manitoba has a relatively small agricultural sector (compared to other provinces), bioprod-
uct firms will have to search a wider geographic area to secure biomass inputs. This point is
further highlighted by the fact that the high price of raw materials or feedstock and unreliable
supply of raw material or feedstock were ranked second and third in terms of important barrier
by Manitoba bioproduct firms.



























Small 3.12 2.58 3.76 4.22 3.78 3.87 4.12
Medium 3.27 2.52 3.55 3.07 3.13 3.63 3.59










Note: The three highest ranked barriers for each region are identified by bold and shaded text.
Table 44 shows the importance of the various barriers based on firm size. For small firms the top
three barriers were lack of financial capital, higher cost and timeliness of regulatory approval
and lack of adequate product standard or certification. The importance of these barriers is not
unexpected.  Small firms often encounter difficulties sourcing capital from various sources
(i.e. lending institutions, venture capitalists, family members, etc.). As well, smaller firms may
lack the resources (either financial or human capital) needed to navigate one's way through the
regulatory approval process, but at the same time, these firms may be saying the regulatory
approval process takes to long. The importance of lack of adequate product standard or certifi-
cate may reflect the fact that smaller firms may have truly novel innovations for which appropri-
ate standards do not exist.  In conjunction with the regulatory approval process issues, it would
seem that smaller firms not only need additional capital, but also see a need for a more flexible
regulatory/standards approval process. 
Table 43: Importance scores for barriers, by region 
Barrier Canada Atlantic Que. Ont. Man. Sask. Alta. B.C.
-number-
Lack of financial capital 3.45 3.64 3.51 3.30 3.16 4.09 3.38 3.25
Higher cost & timeliness of 
regulatory approval
3.17 4.03 3.53 3.05 2.70 2.86 2.73 2.85
Higher price of raw materi-
als or feedstock
2.80 3.09 2.80 2.78 3.37 2.87 2.75 2.60
Unreliable supply of raw 
materials or feedstock
2.70 2.45 2.97 2.58 3.25 2.76 2.28 2.61
Lack of adequate product 
standard or certification
2.70 3.00 2.75 2.53 2.70 2.63 2.75 2.74
Higher transportation cost 
of main feedstock or raw 
material
2.70 2.92 2.49 2.59 3.51 3.00 2.55 2.95
Lack of technology or 
technical information
2.55 2.09 2.57 2.56 3.19 2.28 2.66 2.58
Difficulty to substitute or 
integrate into existing 
processes
2.51 3.08 2.62 2.48 2.50 2.68 2.30 2.15
Lack of skilled human 
resources
2.48 2.49 2.49 2.22 3.01 2.00 2.77 2.73
Negative public perception 
or acceptance
2.10 2.93 1.79 2.12 2.08 1.89 2.22 2.36
Restrictions on intellectual 
property (P) rights






















Note: The three highest ranked barriers for each firm size are identified by bold and shaded text.
For medium sized firms, the top three barriers are the high cost of raw material or feedstock,
higher cost and timeliness of regulatory approval and lack of technology or technical informa-
tion.  The latter barrier is somewhat surprising as one would expect this group of firms to be
more mature than smaller firms and have adequate access to technology and information. The
top three barriers for large firms are: higher transportation cost of main feedstock or raw
material, higher price of raw materials or feedstock and the higher cost and timeliness of regula-
tory approvals.  Larger firms thus perceived higher cost of using bioproducts as a barrier to their
development or production, as well as the regulatory approval process.  
The higher cost and timeliness of regulatory approval is perceived as a universally important
barrier to bioproduct development and production by bioproduct firms in Canada, regardless of
their size. It would thus seem important to develop human capital than enables firms to navigate
their way through the regulatory system. Alternatively, the regulatory system needs to be
modified to make it easier for firms to take a concept from the R&D phase to the market phase of
the innovation spectrum. Also note that the importance of raw material cost as a barrier to
development/production of bioproducts may well lessen as the market for these inputs
develops.
Table 44: Importance scores for barriers, by firm size, 2003
Barrier
Small




(more than 149 
employees)
Unreliable supply of raw materials or 
feedstock
2.78 2.57 2.52
Higher price of raw materials or feedstock 2.69 2.84 3.24
Higher transportation cost of main feed-
stock or raw material
2.57 2.42 3.56
Lack of technology or technical 
information
2.58 2.67 2.28
La\ck of skilled human resources 2.55 2.48 2.24
Lack of financial capital 3.79 2.57 2.98
Difficulty to substitute or integrate into 
existing processes
2.56 2.37 2.40
Negative public perception or 
acceptance
2.00 2.41 2.21
Restrictions on intellectual property (P) 
rights
2.03 1.91 1.90
Higher cost and timeliness of regulatory 
approval
3.27 2.76 3.19
Lack of adequate product standard or 
certification
2.86 2.16 2.64Bioproducts Development Survey: Analysis of the Summary Results 51
Chapter 10
Business Strategies
Respondents to the survey were presented with a series of strategies related to knowledge
development and their overall business and asked to indicate how important each had been for
their firm in 2003 on a five-point scale from “low” (1) to “high” (5). Across the sample as a whole,
the most important strategy related to acquisition of knowledge from other industry sources,
including industry associations, competitors, clients and suppliers (Table 45) and the commence-
ment of new research and development projects. Entering product trials and/or adapting
products for increased market penetration were also important strategies adopted by companies
in the bioproducts sector. Changes in firm size through downsizing or acquisitions, mergers or
joint-ventures were relatively unimportant strategies within the sector as a whole. 
Table 45: Mean importance of strategies for firm, 2003
Strategy Mean Importance Score
Acquired and used knowledge obtained from other industry sources such as industry 
associations, competitors, clients and suppliers
3.3
Began new research and development project 3.2
Entered product trials/adapted products or processes for increased market 
penetration 
3.2
Developed/encouraged staff education/upgrading 3.1
Acquired and used knowledge obtained from public research institutions including 
universities and government laboratories 
3.0
Developed firm policies and practices for knowledge/intellectual property protection 2.8
Expanded into foreign markets  2.7
Used and updated databases of scientific information  2.6
Conducted an intellectual property audit to ensure protection of products and 
processes at all stages of development
2.4
Downsized operations of the firm  1.9











Broadly, across the provinces these same knowledge development and business strategies
remained important for firms engaged in the bioproducts sector across the provinces (Table 46).
However, there were some notable differences. In Quebec, Atlantic Provinces and Saskatchewan
knowledge acquisition through public institutions, including universities and government labo-
ratories, were relatively more important strategies of knowledge development. As discussed
earlier, Quebec is the only province which considers IP audits a fairly important business
strategy. 
Across respondents by company size, the same knowledge development and business strategies
also emerged as most important (Table 47). The most important business strategies across all
firm sizes were new R&D projects and product trials. Knowledge development strategies over-
all, and acquisition and use of knowledge from public research institutions in particular, were of
much less importance for medium-sized firms than either smaller or larger companies.
Table 46: Mean importance of strategies for firm, by region, 2003
Strategy Atlantic Que. Ont. Man. Sask. Alta. B.C.
Knowledge Development Strategies
Acquired and used knowledge obtained from 
other industry sources such as industry 
associations, competitors, clients and suppliers
3.6 3.2 3.2 3.5 3.8 3.2 3.3
Acquired and used knowledge obtained from 
public research institutions including 
universities and government laboratories
3.3 3.3 2.7 2.5 3.4 2.7 3.0
Used and updated databses of scientific 
information
2 . 82 . 82 . 42 . 52 . 82 . 32 . 7
Developed firm policies and practices for 
knowledge/intellectual property protectiong
2.9 3.2 2.5 3.2 2.6 2.6 2.9
Developed/encouraged staff education/
upgrading
3.5 3.2 3.0 3.7 3.1 3.1 2.9
Conducted an intellectual property audit to 
ensure protection of products and processes 
at all stages of development
2 . 23 . 12 . 12 . 61 . 72 . 02 . 1
Business Strategies
Increased firm size through acquisition, merger 
or joint venture 
1 . 52 . 01 . 82 . 21 . 91 . 81 . 8
Downsized operations of the firm 2.0 2.1 1.6 2.6 1.7 1.7 2.1
Entered product trials/adapted products or 
processes for increased market penetration 
3.2 3.4 3.0 3.2 3.4 2.7 3.1
Began new research and development project 3.6 3.5 3.0 2.2 3.3 2.9 3.2




















Table 47: Mean importance of strategies for firm, by firm size, 2003
Company size
Strategy Small Medium Large
Knowledge Development Strategies
Acquired and used knowledge obtained from other industry sources such 
as industry associations, competitors, clients and suppliers
3.19 3.37 3.72
Acquired and used knowledge obtained from public research institutions 
including universities and government laboratories
3.06 2.77 3.23
Used and updated databses of scientific information 2.70 2.46 2.54
Developed firm policies and practices for knowledge/intellectual property 
protectiong
2.95 2.56 2.76
Developed/encouraged staff education/upgrading 3.10 3.23 3.18
Conducted an intellectual property audit to ensure protection of products 
and processes at all stages of development
2.55 1.89 2.29
Business Strategies
Increased firm size through acquisition, merger or joint venture  1.72 1.89 2.25
Downsized operations of the firm 1.87 2.04 1.96
Entered product trials/adapted products or processes for increased market 
penetration 
3.17 3.15 3.12
Began new research and development project 3.20 3.14 3.23
Expanded into foreign markets 2.69 2.80 2.45Bioproducts Development Survey: Analysis of the Summary Results 55
Chapter 11
Discussion and Conclusions
This report provides a first analysis of the Canadian bioproducts sector by province and firm
size. As discussed under limitations its objective was not to answer all of the questions concern-
ing the sector; this could come from a much more in-depth analysis. The report does highlight
some common observations concerning the firms in the business and a number of differences
across the regions and the firm sizes. These were presented in the overview and through the
main report.  The policy implications were also discussed in the overview. However, further
analysis would help in answering some of the questions about why the differences exist and the
role that policy might play in supporting and encouraging the sector across Canada.
Suggestions for improvements to the survey instrument
Initial questions:  It is important to understand the reasons why firms exit the bioproducts
business. Presumably the firms in the current survey will be contacted for the next survey. If they
have exited the business they should be asked why.
• Because the business was not sufficiently profitable
• Sold the business to – another bioproducts firm, a firm in another business, other
• Spun the business off to form a new company
Section 1: Products
Since much of the income from bioproducts firms comes from other product lines a question
should be added to better understand the nature of the most important other product(s) sold by












It would be useful to know if the firm had foreign offices, plants or subsidiaries and if they were
involved in bioproducts and their role - development, sales or supply. This question could
explore the role of multi-national companies. 
Section 5: Human Resources
The HR problem questions are rather restrictive in terms of the categories presented to respon-
dents.  This could be improved with a series of in-depth interviews prior to the design of the
questionnaire.
The questionnaire also only asks for information on employees in Canada.  It would be useful to
include non-Canadian employees in the future.
Section 7:
Many new technology firms secure resources by licensing technologies out to other organiza-
tions.  A question on licensing out should be added. It should collect information on how many
licenses the firm gives out and the nature of the organizations acquiring the licenses.
Section 8: Business Practices
Domestic and foreign collaborations are treated differently.  In domestic collaborations the
objective appears to be to identify the number of collaborations by motivation and partner type.
There is no attempt to understand the strength of the different motivations.  With foreign collab-
oration there is no attempt to determine a number of relationships and the motivations examined
are for a single foreign collaboration, not necessarily the most important foreign collaboration.
This section would provide more useful information if domestic and foreign collaborations
received the same treatment.  
Section 10: Accessing Government Programs
On average, fewer than 40 percent of firms used government programs.  It would be useful to
know why firms are not accessing these programs.  Adding a question examining whether they
did not need the money, did not know about the programs or felt that there was too much paper-
work and administration would be useful. 
Recommendations for further analysis
This report represents the first analysis of the Canadian bioproducts sector.  While the analysis
provides a reasonable overview of the sector it was not intended or able to delve more deeply
into the workings of the sector and the factors contributing to success in bioproduct develop-
ment and commercialization. The analysis contained here was conducted based on regional or
firm size differences.  As one might naturally expect, this is a limited view of what type of intra-
sector differences are present. In this regard, scope exists to develop cross-tabulations that inter-
act not only the regional and firm size variables, but also other variables such as firm age, nature
of business arrangements, the impact of collaborations, etc.  Such analysis will hone our under-



























At the same time, use of multivariate or other statistical methods can be used to test and measure
the relationship between various factors.  Examples include developing models to explain:
• the drivers of bioproduct innovation and biomass use,
• success in obtaining bioproduct development financing,
• the role of intellectual property in bioproduct development and biomass use,
• the role of perceived benefits and barriers to bioproduct development and biomass
use,
• the importance of collaborations in developing and using bioproducts,
• the role of Highly Qualified Personnel in shaping bioproduct development and use,
and 
• the role of alternative business strategies in shaping successful bioproduct develop-
ment and use.
Results from such statistical analysis will again help inform policy makers of the important
drivers shaping firm success in developing and using bioproducts.
This survey also presents an opportunity to create a baseline assessment of the sector and the
firms.  Future studies will facilitate analysis of the development of the sector but also of individ-
ual firms common to this and future surveys.  Firm level, longitudinal analysis will provide
extremely useful information about the nature of firm bioproduct development and the role of
different strategies and policy in shaping that development.  Given that this sector is predicted to
grow at a significant rate over the next few decades, building an understanding of the sector and
critical success factors as early as possible is essential.Bioproducts Development Survey: Analysis of the Summary Results 59
APPENDIX A
Bioproduct Development
by RegionBioproducts Development Survey: Analysis of the Summary Results 60
























Biofuels/bioenergy 77 42 39 120 201 0.86
Biochemicals 77 72 68 292 432 1.86
Biopesticides/biofungicides/
bioherbicides 
39 36 25 83 144 0.62
Fiber composites/fiberboard/
agri-fibre panels
43 30 14 67 111 0.48
Biosensors/biocatalysts/
bioplastics/other
50 53 37 70 160 0.69
Total 232 233 183 632 1,047 4.52
Average products/firm in 
Canada
1.00 0.79 2.72 4.52
Atlantic (15 firms)
Biofuels/bioenergy 8 F x 6 8 0.52
Biochemicals 3 F F 9 12 0.80
Biopesticides/biofungicides/
bioherbicides 
6 x F 8 13 0.84
Fiber composites/fiberboard/
agri-fibre panels
000 0 0 0 . 0 0
Biosensors/biocatalysts/
bioplastics/other
5 F F 9 13 0.87
Total 15 8 5 32 45 3.03
Average products/firm in the 
province
0.53 0.32 2.15 3.03
Quebec (72 firms)
Biofuels/bioenergy 16 18 16 36 70 0.97
Biochemicals 23 34 23 72 128 1.78
Biopesticides/biofungicides/
bioherbicides 
18 24 7 52 83 1.15
Fiber composites/fiberboard/
agri-fibre panels
10 15 4 20 38 0.53
Biosensors/biocatalysts/
bioplastics/other
17 18 9 20 47 0.65
Total 72 109 59 199 367 5.09
Average products/firm in the 
province
1.51 0.82 2.76 5.09Bioproducts Development Survey: Analysis of the Summary Results 61
#
Ontario (53 firms)
Biofuels/bioenergy 17 3 3 18 24 0.45
Biochemicals 19 7 9 78 95 1.79
Biopesticides/biofungicides/
bioherbicides 
30x F 7 0 . 1 3
Fiber composites/fiberboard/
agri-fibre panels
8 4 x x 15 0.28
Biosensors/biocatalysts/
bioplastics/other
12 9 9 12 30 0.57
Total 53 24 27 120 170 3.21
Average products/firm in the 
province
0.45 0.51 2.26 3.21
Manitoba (9 firms)
Biofuels/bioenergy 3 F F F F F
Biochemicals F F F F F F
Biopesticides/biofungicides/
bioherbicides 
X00 0 0 0 . 0 0
Fiber composites/fiberboard/
agri-fibre panels
4xx 1 2 1 4 2 . 9 0
Biosensors/biocatalysts/
bioplastics/other
3F 0 F 5 F
Total 9 12 F 37 F F
Average products/firm in the 
province
1.3 F 3.2 F
Saskatchewan (18 firms)
Biofuels/bioenergy 8 F x 7 12 0.69
Biochemicals 10 x x 28 39 2.16
Biopesticides/biofungicides/
bioherbicides 
Xx 1x x x
Fiber composites/fiberboard/
agri-fibre panels
6 8 x F 12 0.68
Biosensors/biocatalysts/
bioplastics/other
X9 4 1 0 2 3 1 . 3 0
Total 18 24 17 48 87 4.82
Average products/firm in the 
province
1.31 0.93 2.65 4.82
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Notation: Statistics Canada does not report data if it is deemed unreliable or might compromise the confidentiality of a firm. 




Biofuels/bioenergy 12 F x 11 16 0.61
Biochemicals 9 12 9 68 90 3.32
Biopesticides/biofungicides/
bioherbicides 
Xx xx x x
Fiber composites/fiberboard/
agri-fibre panels
4x xx 5 0 . 2 0
Biosensors/biocatalysts/
bioplastics/other
6 9 12 12 33 1.21
Total 27 24 26 95 145 5.34
Average products/firm in the 
province
0.88 0.98 3.53 5.34
British Columbia (38 firms)
Biofuels/bioenergy 12 12 7 26 45 1.19
Biochemicals 11 8 13 29 51 1.33
Biopesticides/biofungicides/
bioherbicides 
10 9 11 18 39 1.01
Fiber composites/fiberboard/
agri-fibre panels
10 x x 21 26 0.69
Biosensors/biocatalysts/
bioplastics/other
5x x5 9 0 . 2 4
Total 38 33 37 100 170 4.47
Average products/firm in the 
province
0.86 0.96 2.64 4.47
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APPENDIX B
Use of Government
Support Programs, 2003Bioproducts Development Survey: Analysis of the Summary Results 64
Firms who used government sponsored programs for the development or production of bioproducts in the last 





Number Reliability Number Reliability
Small (less than 50 employees)
Technology support and assistance program 33 A 17 A
Loan guarantees 3 E 12 A
Export assistance programs 5 A 9 A
Information or internet services 14 A 10 A
Support for training 5 E 15 F
Other 4 E F F
Total number of firms applying 63 A 64 A
Medium (50 - 149 employees)
Technology support and asisstance programs 4 E 3 E
Loan guarantees 0 --- 0 ---
Export assistance programs 0 --- F F
Information or internet services 0 --- 0 ---
Support for training 0 --- 3 E
Other 0 --- 0 ---
Total number of firms applying 4 E 7 E
Large (more than 149 employees)
Technology support and asisstance programs 5 E 6 A
Loan guarantees 0 --- 0 ---
Export assistance programs F F 0 ---
Information or internet services 1 E 0 ---
Support for training F F 3 E
Other 0 --- 0 ---
Total number of firms applying 9 A 9 ABioproducts Development Survey: Analysis of the Summary Results 65
APPENDIX C
Provincial RankingBioproducts Development Survey: Analysis of the Summary Results 66















by candidates too high
25.2 13.5 33.6 19.8 7.9 2.717
Candidates unwillling to 
relocate
36.4 17.1 24.0 7.6 14.9 2.475




20.4 10.7 24.7 19.3 24.9 3.176
External factors
Lack of qualified candidates 24.8 16.7 26.7 23.9 7.9 2.734
Competition for qualified 
candidates




by candidates too high
38.8 10.4 10.4 20.1 20.3 2.727
Candidates unwillling to 
relocate
48.7 0.0 30.5 0.0 20.8 2.442




11.6 20.8 29.3 10.4 28.0 3.227
External factors
Lack of qualified candidates 32.3 8.2 28.8 20.3 10.4 2.683
Competition for qualified 
candidates




by candidates too high
22.2 12.6 34.1 24.9 6.1 2.798
Candidates unwillling to 
relocate
30.3 25.1 22.5 10.3 11.8 2.482




14.9 12.2 24.4 20.2 28.2 3.343
External factors
Lack of qualified candidates 28.3 5.9 26.7 30.6 8.5 2.851
Competition for qualified 
candidates





by candidates too high
26.3 22.2 23.0 26.0 2.4 2.557
Candidates unwillling to 
relocate
34.0 27.7 21.9 5.6 10.8 2.315




18.7 9.8 21.5 24.9 25.1 3.279
External factors
Lack of qualified candidates 20.5 27.1 24.9 24.6 2.9 2..623
Competition for qualified 
candidates




by candidates too high
35.1 14.5 32.0 18.4 0.0 2.337
Candidates unwillling to 
relocate
35.1 14.5 0.0 17.5 32.9 2.986




35.1 32.0 14.5 0.0 18.4 2.346
External factors
Lack of qualified candidates 17.5 32.0 14.5 35.9 0.0 2.686
Competition for qualified 
candidates




by candidates too high
23.5 8.3 40.4 20.8 6.9 2.790
Candidates unwillling to 
relocate
69.8 6.9 14.8 0.0 8.4 1.700




31.4 5.9 15.8 24.5 22.3 3.001
External factors
Lack of qualified candidates 31.4 38.4 22.3 7.9 0.0 2.067
Competition for qualified 
candidates
37.4 25.0 22.3 0.0 15.3 2.308















by candidates too high
17.0 16.8 46.5 10.2 9.6 2.789
Candidates unwillling to 
relocate
26.2 11.0 26.1 16.4 20.4 2.941




22.8 4.6 30.9 20.5 21.1 3.122
External factors
Lack of qualified candidates 17.0 15.5 25.0 20.6 21.8 3.144
Competition for qualified 
candidates




by candidates too high
28.1 4.4 44.1 8.3 15.1 2.779
Candidates unwillling to 
relocate
37.7 4.2 35.6 3.5 19.0 2.619




26.2 6.8 30.1 14.4 22.5 3.002
External factors
Lack of qualified candidates 25.3 13.4 34.2 19.1 8.1 2.716
Competition for qualified 
candidates
25.3 27.9 30.8 7.7 8.3 2.458
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Introduction
The survey provides information on companies that are developing or producing bioproducts
using biomass or other renewable or sustainable feedstocks/materials. 
The survey is carried out by the Science, Innovation & Electronic Information Division. It falls
under the general conditions of the Memorandum of Understanding signed between Agriculture
and Agri-Food Canada and Statistics Canada in April, 2004.
Bioproducts are an emerging sector of the Canadian economy. However, data on the characteris-
tics of firms engaged in developing or producing bioproducts are scanty. This survey will collect
this information and will improve the data available on bioproducts development or production
activities. 
This is the first survey of bioproduct development or production activities in Canada. It follows a
report on bioproducts development by Canadian biotech firms based on information from the
2001 Biotechnology Use and Development Survey. 
The survey addresses the following question: What are the characteristics and activities of firms
that develop bioproducts as an important part of their activities?  Specifically, it collects data on
the characteristics of bioproduct firms including their use of biomass and other renewable/
sustainable biomaterials, the types and number of bioproducts being developed, benefits and
constraints related to developing bioproducts,  human resources devoted to bioproducts, finan-
cial profile, business  practices, access to financing capital  and the use of government support
programs.
Objective of the survey 
The objective of the survey is to gather data on the activities of Canadian firms engaged in the
development or production of bioproducts. Such data will fill major gaps in our understanding
of the changes under way in Canadian firms, thereby improving our knowledge of bioproducts
development and production activities in Canada.
Development of the questionnaire
The questionnaire was prepared with the active participation of partners and in consultation
with a group of bioproducts industry experts offering a range of skills and interests. After the
initial design of the questionnaire, tests were conducted with prospective respondents, whose
comments (design) were incorporated into the final version. 
Definition of a bioproduct 
A Bioproduct is defined as a commercial or industrial product  other than food, feed and medi-
cines  made with biological or renewable agricultural  plant, animal  or forestry materials.  Exam-
ple of bioproducts are bio-fuels, bio-energy, bio-plastics, fiberboards/agri-fiber panels re
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Target population 
The target population for the survey consists of firms that use biomass and other renewable or
sustainable feedstocks/materials to develop or produce bioproducts. 
The first stage of the 2003 Biotechnology Use and Development Survey was used as a vehicle to
identify the bioproducts target population.
Sample
This is a sample survey.
Two types of firms are found in the survey sample: firms that are sampled with certainty, also
referred to as a "must-take-all" list, and those that are sampled randomly. The must-take-all list is
made of firms whose names and addresses are provided by Statistics Canada, industry experts
and other partners to the survey, namely, Agriculture and Agri-Food Canada, Industry Canada
and the provincial/territorial bioproducts industry associations.
The sampling of the second category of firms is based on the enterprise database in Statistics
Canada's Business Register (BR), which contains an Integrated portion (IP) and a Non-Integrated
Portion (NIP). Two main considerations are at play in the selection of these sample units,
namely, to reach the target population and to minimize the response burden. To this end, Gross
Business Income (GBI), R&D expenditures and the number of employees are used as selection
criteria. The selection is also based on three dimensions of the data strata: province/territory,
industrial sector based on the North American Industry Classification (NAICS) codes, and firm
size. 
Industries are surveyed at levels other than 4-digits; small firms with fewer than 5 employees
and with R&D expenditures of less than $100,000 are excluded, as are universities/hospitals,
contract research organizations (CRO) and not-for-profit organizations.
Applying these criteria resulted in a list of 10,427 firms, to which the first-stage questionnaire
was sent. The North American Industry Classification (NAICS) codes that were sampled to
establish this list are shown in Table 1.
Of these 10,427 firms, those indicating that they have developed or produced bioproducts will
receive the second-stage questionnaire. So will all firms on the "must-take-all" list.
Response rate and data quality
The questionnaire was sent to 480 firms. Of these 426 returned the questionnaire, resulting in
89% response rate. Of the returned questionnaires, 161 provided the required information. After
accounting for non-response and applying post-stratification techniques, an estimated 232 firms
were involved in developing or producing bioproducts in Canada in 2003.
The quality of the data was insured by taking into account and applying throughout the survey
process all 6 dimensions of data quality control at Statistics Canada, namely, relevance of data
collected, their accuracy, their timeliness, their accessibility, their interpretability and their
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Science, Innovation and Electronic Information Division Conﬁdential once completed
Collected under the authority of the 
Statistics Act, Revised Statutes of 
Canada, 1985, Chapter S-19.  
Completion of this questionnaire is a legal 
requirement under the Statistics Act. 
Si vous préférez ce questionnaire 
en français, veuillez cocher 
Bioproducts Development 
Survey
Information for the Respondent
Purpose of Survey
Statistics Canada is conducting this survey to produce a proﬁle of ﬁrms engaged in the development or production of 
bioproducts in Canada. The survey focuses on the key characteristics and activities of ﬁrms that develop or produce 
bioproducts as part of their company’s activity.
Bioproducts are an emerging sector of the Canadian economy and their impact has the potential to be felt through all 
parts of the Canadian society. An accurate understanding of bioproducts requires comprehensive data. Information 
from this survey may be used by businesses for economic or market analysis, by trade associations to study industry 
performance, government departments and agencies to assist policy formation, and by the academic community for 
research purposes.
Please report data for 2003 ﬁscal year for bioproducts development or production activities of your ﬁrm in Canada 
unless a speciﬁc question asks otherwise.
Authority
Collected under the authority of the Statistics Act, Revised Statutes of Canada, 1985, Chapter S-19. Completion of 
this questionnaire is a legal requirement under the Statistics Act.
Conﬁdentiality
Statistics Canada is prohibited from publishing any statistics that would divulge information obtained from this 
survey that relates to any identiﬁable business, institution or individual. Data are treated in strict conﬁdence, used for 
statistical purposes and released in aggregate form only. The conﬁdentiality provisions of the Statistics Act are not 
affected by either the Access to Information Act or any other Legislation.
Who should complete this questionnaire?
A knowledgeable senior person in your ﬁrm, such as an R&D manager or production manager, can complete this 
questionnaire.
Assistance
If you have questions or require assistance please contact:
Tel: 1-888-820-1169   or
Fax: 1-888-869-0972
Email: sieidinfo@statcan.ca
Please provide the following information:







- ( )5-5300-506.1 Page  2
Section 1 – Use of Biomass and Development or Production of Bioproducts
This section measures your ﬁrm’s use of biomass and its bioproducts development or production 
activities.
Biomass is deﬁned as renewable or sustainable feedstock/materials of agriculture, animal, forestry, marine or 
aquaculture origins or from municipal and industrial waste.
a) Does your ﬁrm use biomass?  
(please refer to the table below for examples of biomass)
No
b) In the table below, please indicate the types of biomass used by your firm  
(check all that apply).
Yes
Agricultural crop biomass: crops and crop residues,  
dedicated energy crops (switchgrass, wheatgrass, silver maple, hybrid poplar, cottonwood, etc.), 
industrial crops (ﬂax, hemp, canola, corn, etc.)
2010
Forestry biomass: forestry products/slash; mill waste/residues, wood and wood residues
2020
Marine and aquaculture materials/products
2030
Food processing products and by-products: animals, plants
Animal manure
Industrial organic waste (e.g. sludge)
Municipal organic waste (e.g. household waste)










 2.  Use of biomass by your ﬁrm
Number of bioproducts by stage 
of development/production
Yes
A bioproduct is deﬁned as a commercial or industrial product (other than food, feed and medicines) 
made with biological or renewable agricultural (plant, animal) marine or forestry materials.
a) Does your ﬁrm produce or develop bioproducts?  
(please, refer to the table below for examples of bioproducts)
No  ► 
 1. Bioproducts Development and Production





Bio-fuels (methane, ethanol, bio-diesel)




(e.g. bio-solvants, bio-adhesives, bio-surfactants,  
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 6. Is (are) your ﬁrm’s bioproduct(s):  
(check all that apply)
Sold directly to consumers or distributors
Sold to other ﬁrms to be used as input(s)










 7. a) Are the bioproducts development or production activities of your ﬁrm located at an address other 
than that on the questionnaire? 
b) Please provide the address of the location of the bioproducts development or production activities.  
If more than one location, please provide the address to the location where these activities mostly  
take place.
City Province Postal Code
 3. Is the principal biomass input used by your ﬁrm a:  
(Please check one)
Primary product (e.g. soybean, corn, hemp, ﬂax, etc.)
By-product (e.g. straw, fat, etc.)











 5. Does your ﬁrm get or purchase its biomass principally from a:
Domestic source (including production of biomass  
as a result of your ﬁrms’ activities)




If your ﬁrm develops or produces at least 
 one type of bioproducts listed in 1 b)
 OR 
 If your ﬁrm uses at least one type 
 of biomass listed in 2 b)
► Go to question 3
If your ﬁrm does not develop or  
 produce any bioproducts listed in 1 b)
 AND 
 If your ﬁrm does not use any biomass  
 listed in 2 b)
►
Please return the questionnaire 
in the accompanying prepaid 
envelope. Thank you for your 
collaboration.5-5300-506.1 Page  4
Importance
Importance
Unreliable supply of raw materials/feedstock
Higher price of raw materials/feedstock
Higher transportation cost of main feedstock/ 
raw material 
Lack of technology/technical information 
Lack of skilled human resources
Lack of ﬁnancial capital
Difﬁculty to substitute/integrate into existing processes
Negative public perception/acceptance
Restrictions on Intellectual Property (IP) rights 
Higher cost and timeliness of regulatory approval
Lack of adequate product standard/certiﬁcation
Other, please specify:
1
Section 2 – Benefits from developing or producing bioproducts
 8. Please rate the importance of the following beneﬁts obtained by your ﬁrm as a result of 
developing or producing bioproducts.
Reduced production cost
Reduced energy consumption
Reduced damages to the environment
Developed new market niche/new products





8001 2 3 4 5
1 8002 2 3 4 5
1 8003 2 3 4 5
1 8004 2 3 4 5
1 8005 2 3 4 5
1 8006 2 3 4 5
1 8007 2 3 4 5
1 8008 2 3 4 5
► ◄
1
Section 3 – Barriers to developing or producing bioproducts
 9. Please indicate the importance of the following barriers your ﬁrm experienced in the development 
or production of bioproducts by your ﬁrm.
Low High
9001 2 3 4 5
1 9002 2 3 4 5
1 9003 2 3 4 5
1 9004 2 3 4 5
1 9005 2 3 4 5
1 9006 2 3 4 5
1 9007 2 3 4 5
1 9012 2 3 4 5
► ◄
1 9008 2 3 4 5
1 9009 2 3 4 5
1 9010 2 3 4 5
1 9011 2 3 4 55-5300-506.1 Page  5
Section 4 – Firm Characteristics
  10. What year did your ﬁrm become engaged in bioproducts-related activities?
  11. How did your ﬁrm become involved in developing or producing bioproducts? (Please check one) 
Mainly as a result of activities of your ﬁrm (as part of an R&D project)
In co-operation/collaboration with other ﬁrms or organizations
Merger with/acquisition of another ﬁrm
Purchase of another ﬁrm’s bioproducts development activities without merging or acquiring it












a) Is your ﬁrm a spin-off? A spin-off is deﬁned as a new ﬁrm created to transfer and commercialize 
inventions and technology developed in universities, ﬁrms or government laboratories.


























Section 5 – Human resources in bioproducts development or production 
  16. For the purpose of this survey Employees are deﬁned as those workers for whom you completed a 
Canada Revenue Agency T-4 statement for the 2003 tax year. Include working owners. Do not 
include students. Only count employees working in Canada. If an employee performs more  
than one duty, report their primary responsibility. Count each person only once.  
Please report typical employment level for 2003. If ‘0’ (zero) indicate ‘0’.
Number of employees
in 2003
Total number of employees in Canada
Number of employees with  
bioproducts-related responsibilities:  Scientiﬁc research and development  
  (e.g. scientists, R&D managers, 
  industrial postdocs, etc.)
  Technicians
  Management/marketing/ﬁnance/production
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Importance
1
  17. Please rate the importance of the following factors on your efforts to ﬁll bioproducts-related 
vacancies 
Candidate Factors
  Compensation requirements by candidates too high
  Candidates unwilling to relocate
  Lack of experience
Firm Factors
  Capital/resources insufﬁcient  
  to attract candidates 
External Factors
  Lack of qualiﬁed candidates
  Competition for qualiﬁed candidates
  Other, please specify:
Low High
17001 2 3 4 5
► ◄
1 17002 2 3 4 5
1 17003 2 3 4 5
1 17004 2 3 4 5
1 17005 2 3 4 5
1 17006 2 3 4 5
1 17007 2 3 4 5
Section 6 – Firm Financial Profile
Revenues and Research & Development (R&D) Expenditures
  18. Please complete the following table. If information is not available please provide a carefully 
considered estimate. Report data for ﬁscal years.  
If ‘0’ (ZERO) please indicate ‘0’, do not leave blanks.
2002
Total Firm Revenues (all sources)
Revenues from Bioproducts 
% of revenues from Bioproducts exported
Total R&D spending
R&D spending on Bioproducts










No  ► Go to question 20.
19001
▼

























19. a) For bioproducts currently under development or in production,  
did your ﬁrm apply for / acquire / license in the IP rights?
b) Which of the following describes the intellectual property rights obtained? 







c) Were the IP rights acquired from:
Canadian ﬁrms or organizations
Foreign ﬁrms or organizations
19040
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$
Section 8 – Business Practices
Contracting Out













Collaborative arrangements involve the active participation in projects between your company and other 
companies or organizations in order to develop and/or continue work on new or signiﬁcantly improved bioproducts 
processes or products. Pure contracting-out work is not regarded as collaboration.
Collaborative Arrangements
  21. Was your ﬁrm involved in bioproducts-related collaborative arrangements with other 
companies or organizations in 2003?
Bioproducts 
Firm
Knowledge not available internally; 
Access outside scientiﬁc expertise
  


















Number of Arrangements by Partner Type
Yes
No  ► Go to question 23.
21001
▼
Purpose of Arrangement 
Provide the number of arrangements by purpose and partner type:
Collaboration with foreign partners
Yes
No  ► Go to question 23.
22001
▼
Please rate the following purposes in your decision to form a collaborative arrangement with a foreign partner. 
22. In 2003, was your ﬁrm involved in bioproducts-related collaborative arrangements with foreign 
partners? 
Importance
1 Knowledge not available internally 
Access outside scientiﬁc expertise
  





22010 2 3 4 5
► ◄
1 22020 2 3 4 5
1 22030 2 3 4 5











   b) For the ﬁscal year 2003, what was the total value 




1 22040 2 3 4 5
1 22050 2 3 4 5
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Section 9 – Raising Capital 
Yes
No  ► Go to question 28.
23001
  23. a) Did your ﬁrm attempt to raise capital, including government funding, for purposes related to 
bioproducts in 2003?
▼
b) Why did you attempt to raise capital? 
(Indicate each category that applies to your ﬁrm.)
R&D purposes/expand R&D capacity














No  ► Go to question 26.
24001
24. a) Were you successful in raising capital?
▼
b) How much capital did you raise in 2003?
24002
25001 %
Further product development or proof of concept required
Bioproduct not market-ready
No proof of market demand
Insufﬁcient speciﬁc management skills/expertise
Capital not available due to capital market conditions









26. What reasons did the lender(s) give in limiting or refusing your request for capital?  
(Check all that apply.)
27. What sources provided capital? % of total raised 
from each source
Canadian based Venture Capital
American based Venture Capital
Banks, Cooperatives, Credit Union
Angel Investors/Family
Government sources:  Government loans
  Matching funds
  Grants
  Other, please specify:
















25. What percentage of your target did you reach?
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29. During the last three years, did your ﬁrm use any of the following types of programs sponsored by  
the federal or provincial/territorial governments for activities related to the development or production  
of bioproducts? (Please check all that apply.)





Technology support and assistance programs
Loan guarantees
Export assistance programs







Section 11 – Strategies Used in 2003
  30. How important were each of the following strategies for your ﬁrm in 2003?
Knowledge development strategies 
  Acquired and used knowledge obtained from other 
  industry sources such as industry associations, 
  competitors, clients and suppliers 
  Acquired and used knowledge obtained from  
  public research institutions including universities  
  and government laboratories
  Used and updated databases  
  of scientiﬁc information
   
  Developed ﬁrm policies and practices for  
  knowledge/intellectual property protection 
  Developed/encouraged staff education/upgrading 
  Conducted an Intellectual Property Audit to ensure  
  protection of products and processes at all stages  
  of development
Business strategies
  Increased ﬁrm size through acquisition,  
  merger or joint venture 
  Downsized operations of the ﬁrm
  Entered product trials/adapted products or  
  processes for increased market penetration
 
  Began new research & development project 
  Expanded into foreign markets 
  Other, please specify:
Low High
30001 2 3 4 5
1 30002 2 3 4 5
► ◄
1 30003 2 3 4 5
1 30004 2 3 4 5
1 30006 2 3 4 5
1 30007 2 3 4 5
1 30008 2 3 4 5
1 30012 2 3 4 5
Yes
No  ► Go to question 29.
28001
28. a) In the past 5 years, did your ﬁrm apply for beneﬁts for bioproduct related activities under the 





   b) How much did you apply for in 2003?
1 30005 2 3 4 5
1 30009 2 3 4 5
31001








1 30010 2 3 4 5
1 30011 2 3 4 5
28003
   c) What are your cumulative credits?
$ ,000
$ ,000
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Comments
Thank you for your assistance.
Please return the questionnaire in the accompanying prepaid return envelope.